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Zusammenfassung 
Im Jahr 2013 wurde über eine neue Substanzklasse für die Behandlung von Morbus 
Parkinson berichtet, die auf die Auflösung von -Synuclein-Oligomer-Aggregaten 
abzielt.1 Untersuchungen verschiedener Kandidaten zeigen, dass die Behandlung mit 5-
(3-Bromphenyl)-3-(piperonyl)pyrazol (1a) zu einer deutlichen Reduktion der 
Proteinaggregat-Belastung führte. Da der Wirkmechanismus der Proben durch die 
Bindung an -Synuclein-Oligomere erklärt wurde, sollten sich 18F-markierte Analoga 
von 1a potentiell als Tracer nutzen lassen, um -Synuclein-Oligomere, die als Vorstufen 
der Proteinablagerungen gelten, diagnostisch zu erfassen. Das erste 18F-markierte 5-(3-
Bromphenyl)-3-(6-[18F]fluorpiperonyl)pyrazol ([18F]1b) wurde durch 1,3-dipolare 
Cycloaddition zwischen 3'-Bromphenylacetylen (2a) und [18F]Fluorphenyldiazomethan 
hergestellt, welches in situ aus Tosylhydrazon ([18F]3b) erzeugt wurde. Die 1,3-dipolare 
Cycloaddition zwischen dem aus Tosylhydrazon ([18F]3a) hergestellten 4-
[18F]Fluorphenyldiazomethan und 4'-Fluorphenylacetylen (2b) wurde als Modellreaktion 
untersucht, um optimierte Reaktionsbedingungen zu erhalten. Dabei konnte die 
Modellverbindung 3,5-Bis(4-fluorphenyl)-1H-pyrazol ([18F]1d) mit einer 
radiochemischen Ausbeute (RCA) von 67% und [18F]1b mit einer RCA von 27-34% 
erhalten werden. Mit einer weiteren Synthesestrategie wurde eine andere -Synuclein 
adressierende Verbindung 5-(3-[18F]Fluorphenyl)-3-(piperonyl)pyrazol ([18F]1c) 
synthetisiert. Dazu wurden für die kürzlich beschriebene Kupfer-vermittelte 
Radiofluorierung Stannylvorläufer als Substrate eingesetzt.2,3 Trialkylaryl-Zinn-
Verbindungen werden bereits seit einigen Jahrzehnten für elektrophile 
Radiofluorierungen verwendet. Daher sind viele verschiedene Vorläufer für Radiotracer 
zum Teil kommerziell erhältlich. In dieser Arbeit wurde Trimethyl(phenyl)zinn als 
Modellverbindung verwendet, um ein Protokoll für die Cu-vermittelte 18F-
Fluorodestannylierung zu etablieren. Nach Optimierung der [18F]Fluorid-Aktivierung 
und der Destannylierungsbedingungen wurden verschiedene Arylstannylverbindungen 
mit unterschiedlichen elektronischen Effekten in RCA von 16-88% markiert. Der Einsatz 
der optimierten Bedingungen ermöglichte die Radiosynthese von [18F]1c in RCA von 
62%. Weiterhin wurde dieses Verfahren ausgehend von kommerziell verfügbaren 
Vorstufen, zur Synthese von 18F-markierten Arylaminosäuren, verwendet. Dieses 
manuelle Syntheseverfahren wurde dann auf ein vollautomatisiertes Synthesemodul 
übertragen. Dadurch wurden schließlich 3-O-Methyl-6-[18F]fluor-L-DOPA (6-
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[18F]OMFD), 6-[18F]Fluor-L-m-tyrosin (6-[18F]FMT), 2-[18F]Fluor-L-tyrosin (2-[18F]F-
Tyr) und 6-[18F]Fluor-L-3,4-dihydroxyphenylalanin (6-[18F]FDOPA) in hohen isolierten 
RCA von 32-57% hergestellt. Bemerkenswerterweise lieferte die automatisierte 
Radiosynthese von 6-[18F]FDOPA eine RCA von 57%. Die höchste in der Literatur 
beschriebene RCA für 6-[18F]FDOPA betrug bisher 40%.4 Ausgehend von 9,2 GBq 
[18F]Fluorid wurden innerhalb von 65 min 3,5 GBq 6-[18F]FDOPA erhalten, Dies 
ermöglicht die robuste Herstellung von 6-[18F]FDOPA in Aktivitätsmengen, die weit über 
den bisher erreichbaren Aktivitätsdosen liegen. Damit sollte diese Methode den Zugang 
zu aromatischen Aminosäuren deutlich vereinfachen, so dass zu erwarten ist, dass diese 
zukünftig eine höheren Stellenwert in der PET Diagnostik einnehmen werden. 
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Abstract 
In 2013 novel compounds targeting -synuclein oligomer aggregates in Parkinson’s 
disease were reported.1 Especially 5-(3-bromophenyl)-3-(piperonyl)pyrazole (1a) 
showed dramatic therapeutic effects since it was able to eliminate pathological -
synuclein aggregates.1 Therefore, it was assumed that 18F-labeled analogs of 1a are 
potentially useful for the detection of -synuclein oligomers. The first 18F-labeled 
compound 5-(3-bromphenyl)-3-(6-[18F]fluorpiperonyl)pyrazol ([18F]1b) was prepared by 
1,3 dipolar cycloaddition between 3'-bromophenyl acetylene (2a) and 
[18F]fluorophenyldiazomethane generated in situ from tosylhydrazone ([18F]3b). In order 
to establish optimized reaction conditions, the 1,3-dipolar cycloaddition between 4-
[18F]fluorophenyldiazomethane and 4'-fluorophenyl acetylene (2b) was studied as a 
model reaction. Optimized reaction conditions enabled to obtain 3,5-bis(4-fluorophenyl)-
1H-pyrazole ([18F]1d) in radiochemical yield (RCY) of 67%. The same reaction 
conditions delivered [18F]1b in RCYs of 27–34%. The second approach applied in this 
work to obtain the -synuclein targeting compound 5-(3-[18F]fluorphenyl)-3-
(piperonyl)pyrazol ([18F]1c) was based on copper mediated 18F-fluorodestannylation. The 
latter method was recently reported by Scott et. al.2,3 This method highly benefits from 
the fact that trialkylaryl tin compounds are routinely used as precursors for electrophilic 
radiofluorinations. Therefore, a method using stannyl precursors and “nucleophilic 
[18F]Fluoride” should be of high interest for the production of radiopharmaceuticals. 
Initially, trimethyl(phenyl)tin was used as a model substrate to establish the 18F-
fluorodestannylation approach. After reaction optimization, this approach was used to 
label several electron-neutral, -rich and -poor stannyl substrates in RCYs of 16-88%. 
Additionally, 18F-destannylation was used to produce [18F]1c in RCY of 62%. 
Furthermore, this method was applied in the synthesis of 18F-labeled amino acids starting 
from commercially available precursors. Finally, a scalable automated synthesis of 3-O-
methyl-6-[18F]fluoro-L-DOPA (6-[18F]OMFD), 6-[18F]Fluoro-L-m-tyrosine (6-
[18F]FMT), 2-[18F]fluoro-L-tyrosine (2-[18F]F-Tyr) und 6-[18F]fluoro-L-3,4-
dihydroxyphenylalanin (6-[18F]FDOPA) was established affording these compounds in 
high isolated RCY of 32-57%. Remarkably, the automated radiosynthesis of 6-
[18F]FDOPA via Cu-mediated radiofluorination of an appropriate stannane precursor 
afforded RCYs of 57%. Starting from 9.2 GBq [18F]fluoride 3.5 GBq of 6-[18F]FDOPA 
was obtained within 65 min suitable for clinical applications. 
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[18F]FBEM N-[2-(4-[18F]-Fluorobenzamido)ethyl]maleimide 
[18F]FPy-TFP 6-[18F]Fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester 
[18F]SFB N-Succinimidyl 4-[18F]fluorobenzoate 
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1 Introduction 
Applications of radioactive nuclides in biochemistry and physiology provided first 
insights into the dynamics of biochemical processes in living systems.5 Substantially, the 
rapid growth of medical imaging techniques was a pivotal event in clinical practice. These 
techniques enabled objective and quantitative measurements of in vivo phenomena, 
extending a deeper understanding of biological processes, and provoked new discoveries 
in the pathophysiology of diseases and the development of new diagnostic methods.6 As 
a result of molecular processes, morphological imaging visualizes structural and 
physiological alterations in tissue. Usually these events lead to activation or inhibition of 
enzymes, receptors or signal transduction pathways. In contrast, molecular imaging 
exploits the interaction of probes with targets involved in biochemical processes in vivo 
to directly visualize these processes. In 1950´s first concepts utilizing radionuclides for 
medical imaging were developed7 and the first examples of the applications of positron 
emission tomography (PET) were reported.8 
1.1 PET principle 
PET and related hybrid methods like PET/CT (computed tomography) and PET/MRI 
(magnetic resonance imaging) belong to the most important techniques in medical 
imaging. These techniques play a major rule in research, nuclear medicine and drug 
development. In PET target-specific tracers labeled with positron emitter nuclide are 
applied. Since ray penetrating radiation is emitted, direct external monitoring of this 
radiation is possible making PET a noninvasive technique. Another advantage of PET 
imaging is that only very small tracer amounts are required (less than 1 ng) to generate a 
signal with sufficient intensity. Thereby, the generation of pharmacological effects and a 
toxicological risk for the patient is very unlikely. Only the radiation exposure of the living 
organism should be taken into account.9 PET exploits the physical properties of positrons 
to make an accurate quantitation of regional radioactivity in vivo possible. An emitted 
positron interacts with an electron after deceleration in tissue resulting in the annihilation 
of both particles. This annihilation creates two photons that travel antiparallel to each 
other. A pair of external radiation detectors positioned on either side of a positron-
emitting source will register these photons at almost the same time (Figure 1.1). This 
detector pair is connected by a coincidence processing unit that records only signals from 
two simultaneously arrived photons. The spatial resolution of a pair of annihilation 
coincidence detectors is nearly uniform for most of the region located between the two 
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detectors.10 Therefore, only two photons arising from one positron annihilation event will 
be recorded. 
 
Figure 1.1 Principle of positron emission tomography. 
 
The choice of a suitable PET isotope for medical diagnostics is affected by different 
independent constraints. Many aspects have to be considered for its selection, such as the 
intended production route, half-life, chemical reactivity, image resolution, radiation 
exposure and the desired structural design of the PET tracer that must meet certain 
physicochemical and pharmaceutical requirements.9 
Metabolic products and endogenous compounds consist mainly of C-, H-, N-, O-, P- and 
S-atoms in different combinations. The number of radionuclides with appropriate nuclear 
properties, which can be produced at small cyclotrons, is limited. Only the “organic” 
positron emitters like 11C, 13N and 15O can fulfill the requirement of substitution of the 
stable nuclide by its radioactive isotope that does not alter its pharmacokinetic behavior. 
Unfortunately, these radionuclides have very short half-lives which limit its practical 
application with respect to complex preparation procedures and radiotracer application. 
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Consequently, only easily accessible [15O]H2O and [
13N]NH4OH are used as tracers for 
the study of regional blood flow and myocardial tissue vitality, respectively. 11C-Labeled 
tracers are utilized in the majority of cases for brain imaging. However, the application 
of 11C-tracers need on-site production of the tracer because of the short half-life of 11C.9,11 
Nonetheless, 18F is the radionuclide with the highest impact in PET owing to its excellent 
decay properties, easy accessibility in the form of 18F- at a small cyclotron (Table 1.1). 
Moreover, a relatively long half-life of 18F (t1/2=109 min) enables multistep 
radiosynthesis and allows transportation of radiofluorinated probes to distant clinic.9,11,12 
Table 1.1 Decay properties and methods of production of short-lived positron emitters.13,14 
Nuclide Half life Decay Emax of positron Production 
11C 20.4 min  99.9%, EC 0.1% 0.960 MeV 14N(p,)11C 
13N 10 min  100% 1.199 MeV 16O(p,)13N 
15O 2 min  99.9%, EC 0.1% 1.732 MeV 
14N(d,n)15O 
15N(p,n)15O 
18F 109.8 min  97%, EC 3% 0.634 MeV 
18O(p,n)18F 
20Ne(d,)18F 
 
1.2 Radiolabeling with Fluorine-18 
Fluorine chemistry is a steadily expanding research area owing to its impact in clinical 
and molecular imaging and at not least in drug discovery. Fluorine has a small van der 
Waals radius (1.47 Å) and is the most electronegative element in the periodic table (3.98 
Pauling scale). Additional factors for the design of fluorine-containing pharmaceuticals 
are: stability of the C–F bond; and the higher lipophilicity of fluorine substituted 
compounds compared with unsubstituted ones.17 Therefore, fluorine substitution has a 
profound effect on small organic molecules.15,16 Introduction of fluorine has been 
extensively investigated in drug research as a means of enhancing biological activity and 
increasing chemical or metabolic stability. 
In molecular imaging 18F is of particular importance since it represents the nuclide with 
the highest impact in PET research: It is easily accessible at a small cyclotron in the form 
of 18F–. Decay characteristics of 18F make it to an ideal PET nuclide with respect to half-
life and resolution.11,18 The maximum positron energy of 634 keV is the lowest of the 
commonly used PET nuclides and the positron path (≤ 2 mm in water) is in the same 
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range as the highest spatial resolution achievable with modern PET scanners (about 
2 mm).18 
18F can be produced at a small cyclotron using different nuclear reactions (Table 1.1). The 
method used to produce 18F depends on the subsequent chemical transformation. For 
nucleophilic radiofluorination 18F– is produced in aqueous media as 18F– whereas for 
electrophilic radiofluorination 18F is produced in the form of [18F]F2. In order to obtain 
[18F]fluoride for nucleophilic substitutions, the 18O(p,n)18F nuclear process on highly 
enriched 18O-water target is mainly used (Table 1.1). Application of this nuclear reaction 
usually leads to product with high specific activities (SA).19 [18F]F2 for electrophilic 
fluorination can be produced by the 20Ne(d,)18F nuclear reaction. In this case, stable 
fluorine needs to be added to the neon gas target to prevent adsorption of reactive atomic 
18F on the target walls. However, addition of F2 leads to low specific activities of the 
labeled products. 
1.2.1 Electrophilic substitution 
Electrophilic 18F-fluorination is characterized by the reaction of highly polarized 18F with 
an electron rich reactant, like an aromatic system, an alkene, or a carbanion. [18F]fluorine, 
the simplest electrophilic fluoro species, is obtained directly from the irradiated target. 
However, electrophilic fluorination with [18F]fluorine produces a mixture of products 
because of the high reactivity of [18F]fluorine. The use of metal substituted substrates for 
radiolabeling directs the [18F]fluorine attack to the electron rich C-M bond and improves 
the regioselectivity.20–26 Aromatic ipso-18F-fluorodemetalation of aryl trialkyl 
crystallogens (group IVb) and 18F-fluorodemercuration were widely studied under 
different conditions.20–26 Electrophilic carrier-added 18F-fluorodestannylation was found 
to be the best method to produce 18F-labeled aromatics with high radiochemical yield 
(RCY) within short preparation time. This reaction is used currently for the preparation 
of radiolabeled analogues of non-toxic endogenous compounds, such as brain tumor 
tracers: 3-O-methyl-6-[18F]-fluoro-L-DOPA (6-[18F]OMFD) and 2-[18F]fluoro-L-tyrosine 
(2-[18F]F-Tyr);27,28 and dopaminergic metabolism tracers: 6-[18F]fluoro-m-tyrosine (6-
[18F]FMT), L-3,4-dihydroxy-6-[18F]fluorophenylalanine (6-[18F]FDOPA) (Figure 
1.2).29,30 
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Figure 1.2 Amino acids derivatives prepared using electrophilic radiofluorinaiton. 
 
However, electrophilic 18F-fluorination is less favored nowadays, especially, with regard 
to the toxicity of some fluoroaromatic amino acid derivatives31 since products with low 
SA are obtained. 
1.2.2 Nucleophilic substitution 
[18F]Fluoride is commonly produced by the nuclear 
reaction 18O(p,n)18F in aqueous solution using highly 
enriched 18O-water target in highly solvated form.19 In 
order to activate [18F]fluoride, anion-exchange 
cartridges (Figure 1.3) are used to retain [18F]fluoride 
and remove/recover a bulk of 18O-water. Thereafter, 
aqueous solutions of tetraalkyl ammonium bicarbonates 
or alkali metal carbonates/bicarbonates/hydroxides 
together with crown ethers or cryptands are used to elute 
[18F]fluoride from the cartridge. Crown ethers or cryptands are used to enhance 
[18F]fluoride nucleophilicity by capturing alkali metal cation and to enable the better 
solubilization of [18F]fluoride ion in polar aprotic solvents.18 Water is generally removed 
by azeotropic distillation with acetonitrile, to produce anhydrous alkali metal or tetraalkyl 
ammonium [18F]fluoride.32 
Azeotropic drying is time consuming and causes high losses of radioactivity on the vessel 
walls during the multiple azeotropic distillation steps (up to four times). Therefore, 
alternative methods were developed to rapidly prepare reactive [18F]fluoride.33 For 
Figure 1.3 Silica based (left) and polymer 
based (right) anion exchange cartridge 
resins.
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example according to the “minimalist” approach, methanol was used to wash the anion-
exchange cartridge after fixation of [18F]fluoride. Subsequently, [18F]fluoride was eluted 
from the cartridge with a methanolic solution of an onium salt (like ammonium, iodonium 
and sulfonium precursors33 or tetraalkyl ammonium or phosphonium salts33–35). Low-
boiling MeOH was removed within 3 min to produce anhydrous [18F]fluoride onium salt 
ready to use for nucleophilic substitution reactions. 
For nucleophilic substitution reactions, appropriate leaving groups (LG) are required. 
Typical examples for leaving groups used in aliphatic 18F-fluorination are iodide, 
bromide, chloride, tosylate, triflate, mesylate or nosylate. In aromatic systems leaving 
groups like NO2, F, Cl, Br, I, (CH3)3N
+, Ar2S
+, ArI+ are used. For all these leaving groups 
except for iodonium and sulfonium salts the presence of activating substituents (electron 
withdrawing group [EWG]), such as CN, CHO, COR, COOR, and NO2 at the ortho- or 
para-position of the leaving group are mandatory to obtain the radiolabeled product in 
reasonable yields (Figure 1.4).19 
 
Figure 1.4 Nucleophilic aromatic [18F]fluorination (SNAr-[18F]fluorination). 
 
Labeling of electron rich aromatic systems using 18F-nucleophilic substitution is 
challenging and very low RCY are usually obtained.36 To overcome this problem 
multistep syntheses starting from activated aromatic compounds have been developed. 
This multistep syntheses enabled the cGMP production of tracers like 6-[18F]DOPA and 
2-[18F]F-Tyr in fair RCYs using mainly custom-made automated synthesis modules.37 
Radiofluorination via prosthetic groups 
Direct 18F-fluorination methods are seldom applicable for labeling of complex molecules 
(like peptides and proteins) which can be sensitive to heat, organic solvents and/or contain 
acidic protons which interfere with 18F-labeling.11,38 In this case, milder indirect 18F-
labeling methods have to be used. Three strategies may be applied for labeling of sensitive 
bioorganic compounds. 
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The first method uses 18F-labeled small building blocks with a reactive functional group 
(prosthetic groups). Such building blocks are divided into: 
• Amine-reactive prosthetic groups introduced via 18F-fluoroacylation and 18F-
fluoroalkylation reactions, like active esters: N-succinimidyl 4-
[18F]fluorobenzoate ([18F]SFB), 6-[18F]fluoronicotinic acid 2,3,5,6-
tetrafluorophenyl ester ([18F]FPy-TFP) and aldehydes: 4-[18F]fluorobenzaldehyde 
(4-[18F]4a).39,38 
• Thiol-reactive prosthetic groups for labeling cysteine containing peptides via 18F-
fluoroalkylation reactions, like maleimides: N-[2-(4-[18F]-
fluorobenzamido)ethyl]maleimide ([18F]FBEM).39,38 
• Carboxyl-reactive prosthetic groups targeting carboxyl residues by 18F-
fluoroamidation.40 
The second method employs the high affinity of heteroatoms like silicon, aluminum or 
boron for fluoride to form stable M-F bonds. Notwithstanding, the specific activity can 
be increased by reducing the precursor amount below the µg range.38 The feasibility of 
this method was exemplified by labeling different organosilico-bombesin derivatives 
using silicon-fluorine-acceptor (SiFA) technology.41,42 
Another method utilizes biorthogonal reactions like copper catalyzed click chemistry. 
This method benefits from the selectivity of the reaction between the appropriately 
functionalized biomolecules and the corresponding prosthetic group in aqueous media.38 
1.3 Transition-metal mediated aromatic radiofluorination 
Electrophilic 18F-fluorination allows labeling of aromatic compounds only with low SA. 
On the other hand, nucleophilic 18F-fluorination yields products with high SA but 
aromatic nucleophilic radiofluorination is limited to activated aromatic compounds. 
Recently, the concept of late-stage transition-metal mediated 18F-fluorination was 
reported.2–4,43–48 This approach allowed to introduce the 18F-label into aromatic 
compounds regardless of their electronic properties. 
1.3.1 Pd- and Ni-mediated aromatic 18F-fluorination 
Pd-mediated 18F-fluorination was the first reported method for the transition metal 
catalyzed synthesis of 18F-labeled arenes. The procedure consists of the reaction of a 
[18F]Pd(IV) complex prepared in advance which serves as a electrophilic fluorination 
agent in the reaction with an appropriate Pd(II)–aryl compound. After 18F-transfer the 
I n t r o d u c t i o n   P a g e  | 8 
 
 
resulting aryl substituted Pd-complex delivers the 18F-labeled arene via reductive 
elimination (Figure 1.5 A).49 
A further development of this method involves a one-step oxidative 18F-fluorination of a 
Ni(II)-aryl complex with a 18F-fluorination agent generated in situ from a hypervalent 
iodine oxidant and [18F]fluoride (Figure 1.5 B).43 The advantage of the Ni-mediated 
method is the use of only one Ni-complex instead of two Pd-complexes in the Pd-
mediated radiofluorination and less starting material. Thereby, the synthesis time is 
significantly reduced. Unfortunately, the high sensitivity of the oxidant to humidity 
hampers so far widespread application of this radiolabeling procedure.50 
 
Figure 1.5 A. Pd-mediated 18F-fluorination; B. Ni-mediated 18F-fluorination. 
 
1.3.2 Copper-mediated 18F-fluorination 
Numerous Cu-mediated reactions are intensively used in organic preparative chemistry 
for more than a century since the discovery of Ullmann reaction in 1901. This reaction 
enables synthesis of symmetric biaryls via copper-catalyzed coupling of 
arylhalogenides.51 
In the last few years the copper-mediated fluorination of aryl halides52, aryl boron 
reagents (trifluoroborates, aryl boronic acids, aryl boronic acid pinacol esters)53, aryl 
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stannanes54, and (mesityl)(aryl)iodonium salts55 with fluoride under relatively mild 
conditions has been reported. 
Moreover, some of these procedures were translated to 18F-chemistry (Figure 1.6). The 
reported copper-mediated 18F-fluorination protocols were applied to produce various 
radiofluorinated arenes containing electron-donating, -withdrawing and -neutral 
substituents using substrates with different leaving groups. No special precautions were 
necessary and 18F-fluorinations could be carried out under air. However, these pioneering 
methods for copper-mediated 18F-fluorination turned out to be only efficient in small-
scale experiments, but were not well-suited for the production of PET tracers on a 
practical scale (low RCYs or low SAs).35 
 
Figure 1.6 Late-stage copper-mediated 18F-fluorination. 
 
1.3.2.1 18F-Fluorination of (mesityl)(aryl)iodonium salts 
Conventional fluorination of asymmetric diaryliodonium salts 
directs the addition of [18F]fluoride predominantly to the more 
electron-poor arene.56,57 This reaction needs high temperatures 
(over 100 °C) and provides only low RCYs. Regardless of its electronic properties, 
copper-mediated nucleophilic substitution of (mesityl)(aryl)iodonium salts undergo 
sterically-controlled oxidative addition of a nucleophile to the less sterically hindered aryl 
group while mesityl iodide is eliminated.55 This copper mediated method was translated 
to 18F-chemistry by Scott et. al..46 The preparation of diverse radiofluorinated arenes via 
copper-mediated 18F-fluorination of (mesityl)(aryl)iodonium salts using [18F]KF/18-
crown-6 proceeded at 85 °C within 20 min under air.46 The disadvantage of this method 
is the low stability and difficult accessibility of the precursors. 
The hypothesized mechanism for such copper-mediated 18F-fluorinations is illustrated in 
Figure 1.7. It is postulated that the reaction proceeds via a CuI/III catalytic cycle. Anion 
metathesis delivers CuI-F (A), which affords after oxidation with iodonium salt a 
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CuIII-aryl intermediate (B). Subsequently, reductive elimination provides a π-complex 
species C that affords the 18F-fluorinated product and the regenerated CuI catalyst.46,53,58 
 
Figure 1.7 Proposed mechanism of copper-mediated fluorination of (mesityl)(aryl)iodonium salts. 
 
1.3.2.2 18F-Fluorination of aryl boron reagents 
The first protocol for 18F-fluorodeborylation was reported by 
Gouverneur et al..45 Accordingly, arylboronic acid pinacol esters 
were reacted with small aliquots of preliminary azeotropically dried 
K2CO3/[
18F]KF/K222 and tetrakispyridinecopper(II) triflate 
[Cu(OTf)2(py)4].
53,54 Unfortunately, if the procedure was used for a one-pot synthesis, 
RCYs decreased dramatically. This was attributed to the instability of the Cu complex 
under basic reaction conditions.35 Consequently, low base protocol was developed. 
Alternatively, potassium oxalate doped with traces of potassium carbonate and higher 
amounts of Cu(OTf)2(py)4 were used to obtain reasonable RCYs.
4 However, the 
improved procedures suffer from the disadvantage of multiple azeotropic distillation 
steps, which increase radioactivity losses and syntheses time. 
Scott et al. demonstrated that aryl boronic acids are suitable substrates 
for Cu-mediated radiofluorination.47 According to the radiolabeling 
protocol KOTf/K2CO3/[
18F]KF, pyridine and copper(II) triflate 
[Cu(OTf)2] in DMF were applied to produce the desired 
18F-fluorinated 
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arenes.47 Again, in this method a low amount of base was used to avoid strong basic 
conditions. However, the use of the hygroscopic Cu(OTf)2 instead of the bench stable 
Cu(OTf)2(py)2 required more precautions. Furthermore, in optimization studies aliquots 
of previously dried KOTf/K2CO3/[
18F]KF were used. Therefore, radioactivity losses by 
the multiple azeotropic steps were not taken into consideration. Moreover, one-pot 18F-
fluorodeborylation of arylboronic acids furnished radiolabeled arenes in unexpectedly 
low RCYs.59 
1.3.2.3 18F-Fluorodestannylation 
Copper-mediated 18F-fluorodestanylation using copper(II) triflate, 
potassium triflate doped with potassium carbonate and pyridine was 
recently reported.3 Unfortunately, this method suffers from high losses of 
radioactivity owing to the adsorption of [18F]fluoride onto vessel walls of the reactor vial, 
the high hygroscopicity of copper(II) triflate as well as a complex experimental setup 
impeding its widespread application. 
However, the application of aryl stannanes as precursors for radiofluorination have 
substantial advantages. These substances are easily accessible (partly commercially 
available) and already GMP validated for the production of radiopharmaceuticals for 
human applications.3 Furthermore, the Sn−C bond tolerates most of functional group 
manipulations enabling syntheses of complex precursors. 
Further copper-mediated 18F-fluorination 
The use of potassium aryl trifluoroborates as substrates for 18F-
fluorodeborylation under the same conditions like aryl boronic acids was 
reported.2 However, no detailed information about reaction optimization 
studies and RCYs were presented. 
Finally, 18F-fluorodeiodination of aryl iodides was reported recently. This 
method required preincubation of aryl iodide with (t-BuCN)2CuOTf in 
pivalonitrile (t-BuCN) for 10 h followed by 18F-fluorination using [18F]AgF in 
acetonitrile or pivalonitrile at 140 °C for one hour.2 Deiodination requires long reaction 
times which are not compatible with the half-life of 18F. 
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1.4 18F-Labeled tracers for the diagnosis of neurodegenerative diseases 
A hallmark of neurodegenerative diseases is the appearance of misfolded proteins in the 
brain followed by a progressive and chronic loss of neural tissue in brain systems.60 
Classification of these diseases are based on the most important protein related disorders 
as tauopathies, -synucleinopathies, prion diseases, trinucleotide repeat disorders and 
TDP-43 or FET proteinopathies. The most frequent neurodegenerative disease 
Alzheimer’s disease (AD), is not strictly included in these groups but is defined by both 
β-amyloid (A plaques and intracellular tau deposits (Figure 1.8).61 
 
Neurodegenerative diseases can share similar pathological patterns, for instance, α-
synuclein aggregates (PD and dementia with Lewy bodies [DLB]) and dopaminergic 
deficits (PD and some atypical parkinsonian syndromes).60 Therefore, accurate 
differentiation between different neurodegenerative diseases is very important.60 The 
contribution of brain PET for differential diagnostics is increasingly gaining importance. 
For example, amyloid imaging agents like [18F]florbetaben and [11C]PiB bind selectively 
to A plaques fibrils in AD (Figure 1.9). These compounds enable to visualize Aß plaques 
in vivo and provide an important tool to study this disease and to bring AD diagnosis to a 
higher level. 
Figure 1.8 Misfolded proteins in neurodegenerative disease; ALS: amyotrophic lateral sclerosis. FTD MND: 
frontotemporal dementia with motor neuron disease. SD: semantic dementia. bvFTD: behavioral frontotemporal 
dementia. PNFA: progressive non-fluent aphasia. CBD: corticobasal degeneration. PSP: progressive 
supranuclear palsy. LPA: logopenic aphasia. PDD: Parkinson’s disease dementia. CJD: Creutzfeldt–Jakob 
disease. GSS: Gerstmann–Sträussler–Scheinker disease. NFT: neurofibrillary tangle.98 
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Figure 1.9 AD specific tracers. 
 
In contrast, tracers binding selectively to -synuclein oligomers which form pathological 
deposits in PD are still unknown.62,63 Therefore, the dopamine precursor tracer 6-
[18F]FDOPA is used as a surrogate marker for clinical routine purposes to examine 
dopamine terminal function in -synucleinopathies. 6-[18F]FDOPA is used to examine 
the availability of presynaptic dopamine transporters, the activity of aromatic acid 
decarboxylase (AADC) and the enzyme converting L-DOPA to dopamine (Figure 1.10).62 
 
Figure 1.10 DOPA metabolism. 
 
6-[18F]FDOPA PET can demonstrate adaptive changes to putamen dopamine terminal 
dysfunction, detecting internal rises in AADC activity in early PD, which declines later 
with disease progression. In DLB, putamen dopaminergic loss is more symmetrical than 
in PD. However, imaging the pattern of loss of presynaptic dopaminergic function has 
not been proven to be possible as a reliable tool to differentiate PD and multiple system 
atrophy (MSA).62 
The disadvantage of this method is that the enzyme catecholamine-O-methyltransferase 
(COMT) transforms 6-[18F]FDOPA into 6-[18F]OMFD (Figure 1.10). 6-[18F]OMFD can 
also cross the blood-brain barrier (BBB), distributes widely in brain and compromises 
image contrast. To overcome this problem, 6-[18F]FMT which is a substrate for AADC 
but not COMT was developed. 6-[18F]FMT provided better visual contrast and reduced 
the need for complex multi-compartment kinetic modeling.29 In turn, 6-[18F]OMFD was 
applied to visualize brain tumors.28 
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1.5 Comparison of different synthetic routes to 6-[18F]FDOPA 
6-[18F]FDOPA is used routinely for the diagnosis of Parkinson´s disease (PD) and other 
central motor disorders even in their prodromal stage.64 Therefore, many labeling 
strategies were developed to produce this valuable tracer. Table 1.2 summarizes different 
6-[18F]FDOPA synthesis routes based on conventional and transition metal-mediated 18F-
fluorination methods. The conventional electrophilic 18F-fluorination method is used for 
routine production of 6-[18F]FDOPA. The main disadvantage of this method is the low 
RCY and molar activity (MA) of the product. In contrast, conventional three step 
nucleophilic 18F-fluorination synthesis of 6-[18F]FDOPA produced higher yields and MA. 
The Ni-mediated radiofluorination method delivered very low RCYs. Copper-mediated 
methods showed different results depending on the leaving group. 
Table 1.2 Synthesis of 6-[18F]DOPA with different methods. 
 
RCY 
[%] 
ee [%] 
Starting 
dose 
[GBq] 
MA 
[GBq/µmol] 
Time 
[min] 
remarks 
Electrophilic 
“conventional”65 
33±4 
(n=13) 
No 
racemization 
2.2 10.6±2.3 45 Automated 
Nucleophilic 
“conventional”37 
36±3 
(n=8) 
98.2±0.6 185 740-1850 62 
Automated 
multistep 
synthesis 
Ni-mediated50 7±1 
No 
racemization 
6.3 175 50 manual 
Cu-mediated 
(LG=Bpin)4 
40±4 
(n=3) 
>95 5 - 96 Automated 
Cu-mediated 
(LG=I+Mes)46 
1.64 - 55.5 10.73 66 
Automated, 
not 
optimized 
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2 Aims and scope 
A hallmark of Parkinson’s disease (PD), prion diseases, dementia with Lewy bodies 
(DLB) and multiple system atrophy (MSA) is the occurrence of pathological protein 
aggregates. Recently a series of small molecules was reported to bind selectively to prion 
proteins and -synuclein aggregates which have a key responsibility for disease 
development and progression. Furthermore, [3-(benzo[d][1,3]dioxol-5-yl)-5-(3-
bromophenyl)-1H-pyrazole] (1a) represents the most effective candidate as it is able to 
significantly reduce prion protein and -synuclein aggregates (Figure 2.1).1,66,67 
The aim of this work was to prepare 18F-labeled analogs of 1a (Figure 2.1) to evaluate the 
potential of this compound for diagnostic purposes. These tracers could represent the first 
imaging agents for visualization of prion and -synuclein protein aggregates. They would 
allow to detect these pathologies in a very early state of disease development and enable 
the development of novel therapeutic strategies for treatment of patients with 
neurodegenerative diseases. 
 
Figure 2.1 potential a-synuclein 18F-tracers. 
 
Initially, [18F]1b should be synthesized using 1,3 dipolar cycloaddition between the 
corresponding radiofluorinated phenyldiazomethane generated in situ and 3'-
bromophenyl acetylene. 
Since multi-step build up synthesis suffered from low yields it was further envisaged to 
use copper-mediated 18F-fluorination to obtain another α-synuclein targeting compound 
A i m s  a n d  s c o p e   P a g e  | 16 
 
 
[18F]1c depicted in Figure 2.1. For this purpose the recently reported Cu-mediated 18F-
labeling of aryltrialkylstannanes should be applied.3 
Since the literature method suffers from severe limitations, a robust, general and efficient 
protocol for radiofluorination via Cu-mediated 18F-fluorodestannylation should be 
established. Therefore, this method had to be carefully investigated with respect to 
distinct reaction parameters using trimethyl(phenyl)tin as a model substrate. These 
parameters consisted of reaction solvent, temperature, time, water content, and amounts 
of Cu-complex and precursor. Additionally, the preprocessing of [18F]fluoride had to be 
adapted and optimized for the subsequent labeling process. 
The good amenability to automation should be one of the most important requirements of 
the novel labeling procedure. This point should be addressed by the implementation of 
the procedure to the automated production of clinically relevant PET-probes like 6-
[18F]FDOPA, 6-[18F]FMT and others from commercially available stannane precursors. 
Finally, the novel procedure should be used to obtain compound [18F]1c. 
R e s u l t s  a n d  D i s c u s s i o n   P a g e  | 17 
 
 
3 Results and Discussion 
3.1 Multistep synthesis of 5-(3-bromophenyl)-3-(6-
[18F]fluorobenzo[d][1,3]dioxol-5-yl)-1H-pyrazole ([18F]1b) 
The initially developed synthesis of [18F]1b comprised 1,3 dipolar cycloaddition between 
18F-fluorinated phenyldiazomethane generated in situ from the corresponding 
tosylhydrazone ([18F]3) in the presence of a base and 3'-bromophenyl acetylene (2a). 
This transformation was optimized using 4-[18F]fluorobenzaldehyde (4-[18F]4a) to 
produce [18F]1d as a model compound (Figure 3.1). 
 
Figure 3.1 Radiosynthesis of model compound [18F]1d. 
 
The first two steps of the synthesis (18F-fluorination of 4b and radiosynthesis of [18F]3a) 
were previously optimized.68 The 1,3 cycloaddition reaction between [18F]3a and 2b was 
then optimized with respect to solvents, kind of base, reaction time and temperature (c.f. 
Figure 3.2). Reaction kinetics revealed that the reaction was completed after 25 min at 
95 °C and produced [18F]1d in good RCY of 66%. A prolongation of the reaction time 
beyond 25 min did not improve the RCY (Figure 3.2 B). Subsequently, the influence of 
different bases on RCY was determined (Figure 3.2 A). Using the alkali bases, potassium 
carbonate and sodium hydroxide, [18F]1d was prepared in 42% and 44% RCY, 
respectively. 1,8-Diazabicyclo(5.4.0)undec-7-ene (DBU) was less suitable and afforded 
only a RCY of 33%. The highest RCY of 50% was obtained by using lithium tert-
butoxide. The dependency of the RCY on the solvent revealed that propylene carbonate 
(PC) and DMSO were suitable for the preparation of 4-[18F]4a and [18F]3a. However, the 
yield of the cycloaddition between [18F]3a and 2b to produce [18F]1d was low in DMSO. 
Yields of >50% were obtained in PC, MeCN and 1,4-dioxane (Figure 3.2 D). 
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However, the accomplishment of a one pot synthesis in PC as solvent revealed no product 
formation. In contrast, under optimized conditions using LiOtBu in MeCN for 25 min at 
95 °C [18F]1d was obtained with RCY 66±3%. 
Using optimized conditions [18F]1b was synthesized in three steps (Figure 3.3). The 
building block of this synthesis was commercially available 6-nitropiperonal. Screening 
experiments to determine the influence of solvents and temperature on the RCY of 6-
[18F]fluoropiperonal ([18F]4c) showed that DMSO was the most suitable solvent at 130 °C 
for 10 min reaction time. However, the use of this precursor required HPLC purification 
to remove 6-nitropiperonal. Without this purification step the RCY of [18F]3b was very 
low and [18F]1b was finally not obtained. However, this time-consuming purification step 
prolongs the synthesis time and decreases the overall RCY significantly. The activity 
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Figure 3.2 A. Base optimization; B. Reaction time optimization; C. Reaction temperature optimization; D. 
Solvent optimization. 
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amount of the obtained product was sufficient for in vitro experiments but did not enable 
to perform in vivo examinations. To obviate HPLC purification, excess of 6-
nitropiperonal was reduced to 6-aminopiperonal using iron powder and concentrated 
hydrochloric acid in ethanol at 100 °C for 10 min. After that the product was isolated by 
solid phase extraction (SPE) chromatography using a reversed-phase (RP) cartridge. First 
[18F]4c was fixed on the cartridge and 6-aminopiperonal was washed from the cartridge 
with HCl (1 M). However, using this method also low RCYs were obtained and a by-
product was detected in the last step having a similar HPLC retention time as [18F]1b. 
 
Figure 3.3 Three steps radiosynthesis of [18F]1b. 
 
Consequently, an onium salt precursor should be used instead of 6-nitropiperonal. This 
compounds usually allow efficient, time-saving and reliable radiofluorination reactions. 
The main advantage is that it can be usually easily separated from the labeled product 
owing to its positive charge using RP SPE purification.33 
First aryltrimethylammonium triflate salts were selected since these salts are commonly 
used. To obtain an appropriated onium precursor commercially available 6-
bromopiperonal was reacted with an excess of dimethyl amine (40% in water). 
Unfortunately, this reaction did not produce the corresponding 4d. This reaction lead to 
an opening of the methylene bridge in the dioxolane ring forming 4e (Figure 3.4). 
 
Figure 3.4 Substitution reaction of dimethyl amine with 6-bromopiperonal. 
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The repetition of the reaction using one equivalent of dimethylamine and one equivalent 
of potassium carbonate showed again that no product formation occurred after one hour 
reaction time. The resonance structures shown in (Figure 3.5) could give an explanation 
for the observed results. In the piperonal ring, the aldehyde group has a strong electron 
withdrawing effect. In contrast, the dioxolane group is not aromatic, but it disrupts 
signiﬁcantly the electron delocalization and impairs the formation of the induced ring 
current.69 Therefore, the resonance structures alternates between II and III (the blue 
path), rather than between II and IV (the green path). Consequently, formyl group 
stabilize resonance structure III.70–73 
 
Figure 3.5 Proposed resonance structures of 6-substituted piperonal. 
 
Therefore, a nucleophilic attack on the dioxolane carbon is more likely resulting in the 
cleavage of dioxolane ring followed by the formation of product 4e (Figure 3.6).70–73 
 
Figure 3.6 Mechanism of dioxolane ring cleavage in piperonal in solution of aqueous dimethylamine. 
 
To avoid the use of nucleophilic reagents and strong basic reaction conditions, direct 
reductive methylation (Eschweiler-Clarke methylation) of 4f was investigated (Figure 
3.7).74 4f was prepared from 6-nitropiperonal using iron powder and catalytic amounts of 
concentrated HCl in a water/ethanol mixture in very good yields. The reductive 
methylation proceeds under acidic conditions using sodium cyanoborohydride as 
reducing agent (hydride donor). 
 
Figure 3.7 Reductive methylation of 4f. 
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This reaction produced a mixture of mono- and di-methylated products (4d and 4g). The 
variation of reaction conditions (temperature, time, excess of reagents) delivered a 
mixture of 95:5 or 70:30 of 4g and 4d respectively. This mixture could not be separated 
with classical flash chromatography. Only preparative HPLC enabled to separate 4d from 
4g, which was time-consuming and costly due to high solvent consumption (mobile 
phase). Therefore, this route was not further pursued. 
The last method was examined to prepare the desired ammonium salt, was to use 
nucleophilic substitution with dimethylamine hydrogenchloride (Me2NH.HCl) of 
fluoride in 6-fluoropiperonal (4c). This compound was synthesized according to the 
literature starting from 6-fluoroveratrol aldehyde (Figure 3.8).75,76 Demethylation of the 
aldehyde by boron tribromide produced 4h in excellent yield. This compound was easily 
oxidizable under air; therefore, it was alkylated directly with bromochloromethane to 
yield 4c. Consequently, the reaction of 4c with dimethylamine hydrogen chloride in the 
presence of potassium carbonate delivered 4d as the only product in this transformation. 
However, the quaternization under inert conditions of 4d did not deliver the desired salt. 
Methyl iodide as a methylation agent in acetone or in ethyl acetate (EtOAc) did not react 
with 4d, which was always quantitatively recovered. In contrast, the reaction of 
methyltriflate with 4d in dichloromethane (DCM) produced a white precipitate which 
consisted of a product mixture (c.f. Appendix II). Unfortunately, purification of this 
mixture using flash chromatography did not succeed. Moreover, the analysis of the crude 
mixture did not show any trace of the desired product. 
 
Figure 3.8 Synthesis scheme for 6-N,N,N-trimethylbenzo[d][1,3]dioxol-5-aminium salt. 
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In a next step, unusual onium salts with piperonal ring system were examined. The first 
reaction pathway comprised was pyridinium salts that could be prepared by Zincke 
reaction (Figure 3.9). This reaction proceeds over nucleophilic addition of the amine to 
the activated ortho position in pyridinium derivatives, followed by ring opening. After 
that amine exchange, and electrocyclic ring closure should take place. However, heating 
of 6-aminopiperonal and N-(2,4-dinitrophenyl)pyridinium chloride (Zincke salt) did not 
result in product formation. 
 
Figure 3.9 Possible synthesis path of 1-(6-formylbenzo[d][1,3]dioxol-5-yl)pyridin-1-ium chloride. 
 
Finally, the synthesis of triphenylphosphonium salts was examined. The reaction of 
triphenylphosphine with 6-bromopiperonal using 
tris(dibenzylideneacetone)dipalladium(0) as a catalyst to produce the corresponding 
phosphonium salt did not work out. 
Since the preparation of the onium precursor was not successful the opportunity to use 
late-stage copper-mediated 18F-fluorination was considered. In this case, 3,5-disubstituted 
pyrazole with an appropriate leaving group should be synthesized. 
3.2 Preparation of precursors for copper-mediated radiolabeling of 3,5-
disubstituted pyrazoles 
Two methods for the synthesis of 3,5-disubstituted pyrazole derivatives were used (Figure 
3.10). The first method employed 1,3-cycloaddition of diazo species – generated in situ 
from tosylhydrazone – with alkynes.77–79 Tosylhydrazones were easily produced by 
condensation of tosylhydrazide and the corresponding aldehyde. The second method 
utilized the condensation of hydrazine hydrate with 1,3-diketones. The later were 
previously synthesized by the reaction of acid chlorides and ketones.80 
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Figure 3.10 methods for the synthesis of 3,5-disubstituted pyrazole derivatives. 
 
3.2.1 Synthesis of aldehydes and ketones 
Piperonal derivatives for subsequent radiofluorination were prepared for 1,3-
cycloaddition method as following (Figure 3.11): synthesis of 4c was described earlier. 
Iodination of piperonal alcohol with iodine and silver trifluoroacetate followed by the 
oxidation of hydroxyl group with pyridinium chlorochromate (PCC) produced 4i as 
described in the literature.81 4j was prepared from the corresponding boronic acid (4m) 
and pinacol. Additionally, treating 4m with potassium bifluoride produced 4k in good 
yield. Finally, 6-bromopiperonal was treated with hexamethylditin using Pd(PPh3)4 as 
catalyst to produce 4l. 
 
Figure 3.11 Synthesis of different piperonal derivatives for the synthesis of radiofluorinated pyrazole derivatives. 
 
For 1,3-diketones method different acetophenone derivatives were synthesized (Figure 
3.12). Methylation of piperonal using methylmagnesium bromide produced the alcohol 
5a, that was iodinated with iodine in the presence of silver trifluoroactate to deliver 5b. 
The oxidation of 5b with PCC produced 6a in excellent yield. Like piperonal, 6-
bromopiperonal was methylated and oxidized to produced 5c and 6b respectively. 
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Bromine in the later was then substituted with trimethyltin using Pd(PPh3)4 to produce 
6c. Finally, the nitration of 3′,4′-(methylenedioxy)acetophenone with nitric acid (65%) 
yielded 6d. 
 
Figure 3.12 Synthesis of different acetophenone derivatives. 
 
3.2.2 Synthesis of acetylene 
To prepare 2a Coery-Fuchs reaction was the method of choice (Figure 3.13 A). This 
reaction included two sequential steps. The addition of 3-bromoaldehyde to a reagent 
prepared from interaction of zinc dust, triphenylphosphine, and tetrabromomethane 
produced 7. However, the reaction of this compound with n-BuLi followed by hydrolysis 
was not successful and did not produce the desired terminal acetylene. 
 
Figure 3.13 Synthesis of 2a. 
 
Another reaction starting from 3-bromocinnamic acid was successful and produced 2a in 
10 g scale (Figure 3.13 B). The reaction consists of two steps. The first step includes 
bromination of 3-bromocinnamic acid with sodium perborate that readily oxidizes sodium 
bromide to produce compound 8 in good yields. The second and last step was the 
elimination reaction using potassium carbonate in DMSO. The advantage of this method, 
that both steps do not require any precautions or inert conditions. 
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3.2.3 Synthesis of precursor using 1,3-cycloaddition reaction 
Primary experiment utilized the procedure reported by Aggrawal et. al. to synthesize 1d 
(Figure 3.14).77 This procedure required excess of the acetylene derivative and long 
reaction time and provided 1d with low yield. 
 
Figure 3.14 Synthesis of 1d after Aggrawal et. al. procedure. 
 
Therefore, the synthesis of 1 were carried out using the optimized conditions from [18F]1d 
synthesis. Thus, 1 were regioselectively produced by 1,3 dipolar cycloaddition of 2a with 
in situ generated diazo compound (Figure 3.15). The later was promoted from 
tosylhydrazones 3 in the presence of a base. Tosylhydrazones 3 were synthesized using 
always the same procedure. Aldehyde 4 was stirred at ambient temperature with 
tosylhydrazide, after 2 h the product precipitated and was easily filtered off. The yield of 
3 was very good but not in the case of 3g. The product did not precipitate and 4l was not 
completely reacted after 24 h. Therefore, chromatography purification was required to 
isolate the product, which was partly lost during the purification process. 
The synthesis of 1 was carried out as one-pot two sequence synthesis starting directly 
from the aldehyde 4. This alternative did not affect the yield. Moreover, the use of toluene 
instead of MeCN at 95 °C produced the same products yield. However, this method 
produced a lot of by-products that required twice or thrice gravity chromatography 
purification using different mobile phases or multiple recrystallizations. Consequently, if 
the reaction was carried out under argon atmosphere and inert conditions some by-
products disappeared, but multiple purification steps were always required. 
 
Figure 3.15 Synthesis of pyrazole 1 over 1,3-cycloaddition of diazo compound and alkyne 2a. 
 
In these method aldehydes 4j-m and tosylhydrazones 3d,e did not produce the desired 
pyrazole. Monitoring the reaction with mass spectroscopy (MS) under variation of 
R e s u l t s  a n d  D i s c u s s i o n   P a g e  | 26 
 
 
reaction conditions (1,4-dioxane instead of MeCN or toluene and the use of DBU or 
K2CO3 instead of LiOtBu) did not show any traces of the desired products. 
To synthesize appropriate precursor for copper-mediated 18F-fluorination the substitution 
of iodine in pyrazole 1e was tested (Figure 3.16). First, Miyaura borylation reaction was 
carried out with 1f using Pd(dppf)Cl2. This transformation did not proceed and 1f was 
quantitative recovered. Then the oxidation of 1f with 3-chloroperoxybenzoic acid (m-
CPBA) in DCM produced precipitate of 1e. The use of 1g did improve the results and did 
not produce the desired iodonium salt. 
 
Figure 3.16 Substitution of iodine in 1e-g with a leaving group. 
 
Additionally, the substitution of 1e with hexamethylditin using Pd(PPh3)4 as catalyst 
produced the protonated pyrazole 1a. The reaction was repeated under more precautions 
and adding molecular sieve to the reaction mixture. Consequently, the product was 
detected in MS of the reaction crude mixture. However, after flash chromatography 
purification the product decomposed and produced always 1a. Thus, synthesis of 1h was 
then carried out over 1,3-diketones method to overcome flash chromatography 
purification of 1h. 
3.2.4 Synthesis of precursor using 1,3-diketones/enolate route 
To overcome the multi purification steps of 1 synthesized over 1,3-cycloaddition another 
method was tried. The acetylation of in situ generated enolate of 6 was found to be very 
efficient to produce enolate 9. This product (9) was confirmed by NMR and no 1,3-
diketone was detected. Consequently, condensation of the produced enolate 9 with 
hydrazine mono hydrate produced 1 with excellent purity (Figure 3.17). 
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Figure 3.17 Synthesis of pyrazole 1 over 1,3-diketones/enolates. 
 
This reaction was carried out using literature modified procedure.80 Subsequently, it 
proceeded over two steps and delivered pure products. However, this method as the 
previous one was not tolerant with some functional groups like trimethylstannyl and nitro 
(6c, 6d). In the case of 6c the second reaction step with hydrazine mono hydrate produced 
1h according to MS of crude mixture (c.f. Appendix II). 
However, the reaction produced by-products. Thus, the 
mixture was purified with flash chromatography. The 
trimethyltin peak in NMR of the isolated fraction 
disappeared and MS of purified product detected 1a. 
That indicate the instability of this compound during 
purification. 
Additionally, the implementation of Miyaura borylation 
on 1f delivered the same results as before and 1f was 
quantitative recovered. This could be attributed to 
Pd(dppf)Cl2 tendency to bond to pyrazole nitrogen, where Boc rest could play the role of 
a ligand (Figure 3.18).82–84 On the other hand, the use of Pd(PPh3)4 to substitute bromine 
in 1j produced always 1i. The cleavage of Boc protecting group in this reaction support 
the hypothesis that the used palladium(II) complex with this system could bond to 
pyrazole nitrogen that restrain the catalytic cycle. 
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Figure 3.18 Proposed ligand exchange of Pd(dppf)Cl2 and 1f. 
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3.3 Optimization of copper mediated 18F-fluorination and synthesis of different 
model compounds and tracers 
3.3.1 18F-Fluorodeborylation 
In primary experiments, the feasibility of copper-mediated 18F-fluorodeborylation was 
examined. 18F-Fluorination of arylboronic acid pinacol ester precursors using 
Cu(OTf)2(py)4 and [
18F]KF/K222 in DMF at 110 °C for 20 min under air was first 
described by Gouverneur et. al.45 This procedure afforded [18F]10, 4-[18F]11, and 3-
[18F]4a in good RCYs of 66-76% if small aliquots of previously dried [18F]KF/K222 were 
used. However, under the described conditions in the literature, one-pot radiosynthesis 
provided [18F]10, 4-[18F]11, and 3-[18F]4a in only 5–7% RCYs. This difference is 
attributed to the excess of base used in the one-pot procedure. In contrast, reducing the 
base amount (0.06 mg K2CO3 instead of 2.8 mg) afforded 
18F-labeled model compounds 
in high RCYs of 41–64% (Table 3.1).35 
Table 3.1 RCYs using different base amounts. 
Product 
 
3-[18F]4a 
 
4-[18F]11a 
 
[18F]10a 
High base RCY [%] 5 7 7 
Low base RCY [%] 41 42 64 
 
3.3.2 18F-Fluorodestannylation 
The focus of this work was to improve and optimize copper mediated 18F-
fluorodestannylation. The results from optimizing copper mediated 18F-
fluorodeborylation confirm that low base amounts should be used in this transformation. 
Additionally, bench stable Cu(OTf)2(py)4 should be used instead of hygroscopic 
Cu(OTf)2. Consequently, optimization of [
18F]fluoride preprocessing is very important 
for this reaction. Moreover, optimization with regard to different solvents, reaction 
temperature and reaction time is mandatory. 
In primary experiments, the elimination of [18F]trimethylfluoride was not detected in the 
reaction mixture of Et4N[
18F] and trimethyl(4-methoxyphenyl)tin in the presence of 
Cu(OTf)2(py)4 in DMA at 100 °C for 10 min. However, the presence of impurities of 
trimethyltin chloride gave raise to a by-product in the reaction mixture. This by-product 
disappeared after eliminating any trimethyltin impurities. This indicated that anion 
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metathesis and disproportionation of copper(II) occurred before the transmetalation step 
which leads to release of trimethyltin triflate in the proposed mechanism (Figure 3.19). 
Moreover, the raise of high-valent copper(III) species seems to function as an electron 
acceptor with higher fluorophilicity than tin which reduces the possibility of eliminating 
[18F]trimethylfluoride in the transmetalation step. Consequently, the reaction starts with 
anion metathesis between copper(II) triflate and the 18F-fluorination reagent.54 
Subsequently, disproportionation of Cu(II) to Cu(III) and Cu(I) species proceeds since 
the reaction is conducted under an air atmosphere.85 Then, the copper(III) species 
undergoes transmetalation. Finally, the 18F-fluorinated product is formed after reductive 
elimination. 
 
Figure 3.19 Proposed 18F-fluorodestanylation mechanism. 
 
3.3.3 General optimization 
The preparation of [18F]fluoride for 18F-fluorodestannylation reaction was first optimized. 
To accelerate this process MeOH was used instead of water and different tetraethyl 
ammonium salts (Et4NX) were used to recover [
18F]fluoride from the anion exchange 
cartridge (QMA-CO3). After fixing [
18F]fluoride on the cartridge, it was rinsed with 
anhydrous MeOH. Then, various amounts of the salts were utilized to minimize the base 
contents in the reaction (Figure 3.20). Thus, 2.5 µmol of any tetraethylammonium salt 
was found to be sufficient to recover over 95% of [18F]fluoride from the cartridge. 
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Figure 3.20 [18F]Fluoride recovery using different Et4NX salts. 
 
Subsequently, the reaction of the recovered alcoholic Et4N
18F solution with 
trimethyl(phenyl)tin (10b) and Cu(OTf)2(py)4 in DMA was considered as a prototype 
reaction to optimize different parameters (cartridge, fluorination reagent, temperature, 
solvent, time, water content, precursor and Cu(OTf)2(py)4 amount). 
 
Further investigations in our group showed that copper-mediated 18F-fluorination of 
arylboronic acid, arylboronic acid pinacol ester or aryltrimethyl tin is tolerant if solvents 
mixtures of alcohol and DMA are used.59 This could be explained by the formation of 
alcohol solvated fluoride “flexible fluoride” (Figure 3.21).86 This fluoride species and 
alcohol solvated copper (II) triflate accelerated the anion metathesis in the proposed 
mechanism (Figure 3.19). Moreover, alcohol could assist boron-copper transmetalation, 
which is an unfavorable reaction.87,88 This finding has the advantage of performing the 
labeling reaction after recovering [18F]fluoride from anion exchange cartridge with no 
need for drying. 
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Figure 3.21 The influence of on alcohol anion metathesis. 
 
Therefore, alcohol screening to confirm this finding in 18F-fluorodestannylation was 
performed. Accordingly, n-butanol and n-pentanol produced high RCYs that decreased if 
alcohols with decreased chain length like MeOH or EtOH was used. Reciprocally, the use 
of n-butanol or n-pentanol produced lower [18F]fluoride recovery (15-20% activity loss 
on the anion exchange cartridge) compared to alcohols with shorter chain length like 
MeOH (Figure 3.22). 
 
Figure 3.22 Alcohol screening. 
 
After base and alcohol optimization, different anion exchange cartridges with different 
counter ion were tested. Three commercially available anion exchange cartridges were 
tested (Figure 3.23). [18F]Fluoride recovery from silica based QMA-CO3 cartridge was 
comparable with polymer based StrataX and Chromafix. While carbonate as counter ion 
on StrataX produced higher [18F]fluoride recovery but lower RCY compared to 
bicarbonate as a counter ion. However, the best recovery and RCY was obtained using 
QMA-CO3. Moreover, other 
18F-fluorination reagents were also compared with tetraethyl 
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ammonium bicarbonate and triflate. The recovery of [18F]fluoride was comparable 
between KOTf, Bu4POMs, Et4NBC and Et4NOTf. But the best RCYs was obtained in the 
case of Et4NOTf. 
 
Figure 3.23 Testing different anion exchange cartridges with different counter ion and different 18F-fluorination 
reagents. 
 
After that, the kinetics of this reaction was studied. Interestingly, 18F-fluorodestannylation 
proceeded just after 5 min at 100 °C and no significant change in RCY was noticed even 
after prolonging the reaction time (Figure 3.24 A). Raising the reaction temperature from 
80 °C to 100 °C increased the RCY considerably. Nevertheless, a reaction temperature 
higher than 100 °C did not improve the RCY (Figure 3.24 B). After that, different 
solvents mixtures were tested. The mixtures consisted always from three parts n-BuOH 
and seven parts of an aprotic solvent (Figure 3.24 C). The reaction did not proceed if 
pyridine, N-methylformamide (NMF) or t-BuOH was used. The use of anhydrous DMF 
and DMSO produced less than 10% RCY. Moreover, the incubation using commercial 
tetramethylurea (99% pure) produced less than 30% RCY. Only anhydrous N-methyl-2-
pyrrolidone (NMP) and DMA produced over 70% RCY. Consequently, the water content 
in the reaction mixture was examined (Figure 3.24 D). The contamination of the reaction 
mixture (n-BuOH:DMA 3:7, 1 mL) with water (5 µL) halved the RCY. Moreover, 
increasing the amount of water (10 µL) further halved the RCY. 
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Then the ratio of n-BuOH to DMA was varied to examine the influence of n-BuOH on 
18F-fluorodestannylation (Figure 3.25). Methanolic Et4NBC was used to recover 
[18F]fluoride. Then the incubation in pure DMA delivered RCY of 80%. A mixture of n-
BuOH:DMA (1:9) show a comparable RCY, if [18F]fluoride was recovered with n-BuOH. 
Moreover, the higher the n-BuOH fraction in the solvents mixture, the lower was the RCY 
of [18F]10a. Additionally, the experiments were repeated using always methanol to 
recover [18F]fluoride. Consequently, the use of DMA, n-BuOH:DMA (1:9) or t-
BuOH:DMA (1:9) produced the similar RCY. However, MeOH as a protic solvent to 
recover [18F]fluoride was superior to n-BuOH. Furthermore, activity loss on the anion 
exchange cartridge was reduced. MeOH was found to be the best alcoholic solvent for 
[18F]fluoride recovery and DMA was the best solvent for 18F-fluorodestannylation. 
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Figure 3.24 Screening of reaction time (A), reaction temperature (B), aprotic solvents (C) and water content 
(D). 
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Finally, the amount of precursor and Cu(OTf)2(py)4 concentration in the reaction mixture 
was reduced (Figure 3.26). Reduction of precursor simplifies later purification steps of 
the labeled product and decreases the radiosynthesis costs. The RCY was over 70% if 
precursor concentration remained beyond 30 mM. Also, the amount of Cu(OTf)2(py)4 
solution should not drop below 30 mM. Reduction of precursor concentration below 
20 mM under the same conditions, reduced the RCY to about 10%. Further reduction to 
10 µmol produced 20% less RCY. 
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Figure 3.26 Optimization of Cu(OTf)2(py)2 and precursor concentration. 
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The variation of Cu(OTf)2(py)4 using 30 mM precursor showed similar results. The use 
of 20-40 mM Cu(OTf)2(py)4 solution produced RCY of >60%. However, loss of more 
than 10% was noticed if lower amounts of 10 mM Cu(OTf)2(py)4 were used. 
3.3.4 Synthesis of 18F labeled model compounds and [18F]1c 
Utilizing these results different model compounds and novel tracers were prepared under 
optimized reaction conditions (DMA, 100 °C, 10 min). It was found that the use of tert 
butyl, trimethylsilyl or trimethyl germane as leaving groups under these optimized 
conditions did not produce the desired labeled compounds. Only trimethyl tin derivatives 
afforded the desired labeled compounds in good yields (Table 3.2). The use of 
tributylstannyl and trimethylstannyl precursors afforded different RCY using different 
compounds. In the synthesis of [18F]10a with the tributylstannyl precursor higher RCYs 
were obtained compeered to trimethylstannyl derivative. On the contrary, the 
trimethylstannyl precursor afforded better RCY than the tributylstannyl precursor if 4-
[18F]11a was prepared. Additionally, ortho substituted compounds were not easily 
accessible using this method. 2-[18F]11a was produced in RCY of 16%, while [18F]4c and 
[18F]3b could not be prepared by this method. Furthermore, 18F-fluorodestannylation was 
not suitable to label small electron rich heterocycles like pyridine, furan and thiophene. 
Table 3.2 18F-Fluorinated model compounds, conventional commercially available and novel potential tracers. 
 
 
34±2% (SnMe3) 
 
72±4% (SnMe3) 
88±1% (SnBu3) 
 
17±1% (SnMe3) 
 
16±1% (SnMe3) 
 
84±2% (SnMe3) 
 
59±3% (SnMe3) 
44±2% (SnBu3) 
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0% 
 
0% 
 
0% 
 
0% 
 
1% (SnMe3) 
 
62±8% (SnMe3) 
 
6±1% (n=2) 
 
5±2% (n=4) 
 
3.3.5 Synthesis of [18F]4c as a building block for the synthesis of [18F]1b 
Copper-mediated 18F-fluorination of 4j-m did not produce [18F]4c (Figure 3.27). The 
variation of reaction time and solvent did not afford any traces of [18F]4c. Only metal-
free 18F-fluorination of 6-nitropiperonal was an appropriate method to synthesize [18F]4c 
in good RCY. 
 
Figure 3.27 Copper-mediated 18F-fluorination of 4j-m. 
 
Therefore, the only synthetic route of [18F]1b was found to proceed over three a step 
synthesis described in the first part of this work. 
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3.3.6 Optimization of 18F-fluorodestannylation of amino acid derivatives 
18F-Fluorodestannylation of commercially available stannylated amino acid precursors 
afforded only a poor RCYs (5-6%). Therefore, further optimization studies using these 
precursors were performed. Synthesis of 6-[18F]OMFD was optimized with respect to 
solvents and Cu(OTf)2(py)4 concentration (Figure 3.28). The commercially available 
precursor is di-Boc protected with a free proton on the amine group. This proton could 
suppress the nucleophilicity of [18F]fluoride and reduce the RCY. Therefore, tri-Boc 
protected precursor was also tested under the same conditions. 
 
Figure 3.28 18F-fluordestannylation of OMFD precursor. 
 
If the di-Boc protected precursor was used with n-BuOH:DMA (3:7) mixture as solvent 
the RCY was improved to 22%. Furthermore, an improvement of 2% and 5% in RCY 
was obtained if excess of Cu(OTf)2(py)4 1.5 eq. and 2 eq. were used, respectively. 
However, tri-Boc protected precursor produced higher RCYs if 1 eq. of Cu(OTf)2(py)4 
was used in DMA. This high RCY decreased if n-BuOH was added to the reaction 
mixture (Figure 3.29). 
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Figure 3.29 Influence of solvent and the concentration of Cu(OTf)2(py)4. 
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The increased RCY in 18F-fluorodestannylation of di-Boc protected precursor if n-BuOH 
was added could be assigned to the formation of alcohol solvated fluoride “flexible 
fluoride” that reduce the interaction between the amine proton and [18F]fluoride.89,86 
After this optimization, commercially available amino acid derivatives were further 
protected with a Boc group and then radiolabeled followed by hydrolysis. The RCY was 
very high; however, the deprotection of ethylester precursors was only feasible by using 
concentrated hydrobromic acid (48%) at 130 °C (Figure 3.30). Subsequently, the manual 
radiosynthesis was transferred to an automated module to test the 18F-
fluorodestannylation procedure using higher radioactivity amounts. 
 
Figure 3.30 HPLC determined RCY of different amino acid derivatives. 
 
3.3.7 Automation radiosynthesis of amino acid derivatives 
The automation of amino acid derivatives radiolabeling was carried out in a two reactor 
apparatus. Figure 3.31 below shows a sketch of the module used in the synthesis. 
[18F]Fluoride was loaded on to a QMA-CO3 cartridge from the female side through V2 
(Valve 2) and V4. After that the cartridge was rinsed with anhydrous MeOH using the 
same path. In the reverse direction, [18F]fluoride was recovered using methanolic solution 
of Et4NOTf over V3-V4 to the first reactor. After removing methanol under reduced 
pressure of dry air the corresponding precursor and Cu(OTf)2(py)4 was added over V32 
without precooling. After the incubation, the mixture was cooled and quenched with 
water. This step produced a precipitate of the hydrophobic precursor. Thus, the transfer 
of this heterogenous mixture to Sep-Pak C18 Plus Long cartridge was slow and caused 
30% radioactivity loss on the reactor wall in the 6-[18F]OMFD synthesis. The cartridge 
was then rinsed with water to remove DMA, Cu(OTf)2(py)4 and Et4NOTf/Et4N
18F. The 
retained activity was then recovered with DCM into the second reactor. DCM was 
removed under reduced pressure of helium followed by the addition of concentrated HBr 
(or HCl in the case of OMFD). The use of FFKM valves (from Christian Bürkert GmbH 
& Co. KG, Ingelfingen, Germany) enabled the use of concentrated acids without causing 
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any problems. After hydrolysis, the mixture was cooled and diluted with NaOH and 
HPLC mobile phase. Finally, the diluted mixture was loaded onto the preparative HPLC 
for purification. No racemization was detected in the product. 
 
Figure 3.31 Sketch of synthesis module. 
 
The purification was carried out using Synergi™ Hydro-RP (250×10) HPLC column. The 
separation was acceptable but the use of Synergi™ Hydro-RP (150×21.2) HPLC column 
allowed better separation and delivered products with very high chemical purity. 
In this module 6-[18F]DOPA, 6-[18F]FMT and 2-[18F]F-Tyr were successfully produced 
in high RCY, over 99% RCP and very good chemical purity. The synthesis of 6-
[18F]OMFD produced very low RCY because of its high lipophilicity. Therefore, the 
automated synthesis of 6-[18F]OMFD should be further optimized. 
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Figure 3.32 Isolated RCY of amino acid derivatives. 
 
The MA of isolated amino acid derivatives were determined. Furthermore, copper and tin 
content in the isolated solution was also summarized in Table 3.3. Copper content in 6-
[18F]DOPA and 2-[18F]F-Tyr was very high. Therefore, after loading the reaction mixture 
on C18 cartridge more water was used (10 mL instead of 5 mL) to wash out the excess of 
copper complex. Thus, the copper content in 6-[18F]OMFD and 6-[18F]FMT was much 
lower. 
Table 3.3 Molar activity and Cu and Sn content of amino acid derivatives solution. 
 6-[18F]DOPA 6-[18F]FMT 2-[18F]F-Tyr 6-[18F]OMFD 
MA [GBq/µmol]  39 50 27 
Sn [ng/mL] 324±16 65.8±3 292±8 50.4±1.2 
Cu [ng/mL] 2560±120 71.8±2.8 4220±220 208±12 
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4 Conclusion 
One of the aims of this study was the preparation of 5-(3-bromphenyl)-3-(6-
[18F]fluoropiperonyl)pyrazol ([18F]1b) and 5-(3-[18F]fluorophenyl)-3-(piperonyl)pyrazol 
([18F]1c) as tracers potentially suitable for the visualization of the deposition of 
pathological -synuclein oligomers in Parkinson’s disease. 
For the preparation of [18F]1b, 1,3 cycloaddition between a diazo species generated in 
situ from 18F-labeled tosylhydrazone and an acetylene derivative was optimized. Under 
optimized conditions the reaction of tosylhydrazone ([18F]3b) and 3'-bromophenyl 
acetylene (2a) produced [18F]1b in 27–34% RCY. However, the overall RCY of [18F]1b 
the starting from [18F]fluoride was only 1% on three steps. 
The second probe, [18F]1c, was prepared using Cu-mediated nucleophilic 18F-
fluorodestannylation of easily accessible 5-(3-trimethylstannylphenyl)-3-
(piperonyl)pyrazol (1i). The preliminary meticulous optimization of 18F-fluoride 
preprocessing and different reaction parameters (reaction time, reaction temperature, 
solvents, water content, amounts of Cu-complex and stannane precursor) carried out for 
several model compounds allowed to prepare them in 16–88% RCY. The newly 
developed protocol enabled the one step preparation of [18F]1c in 48% RCY. 
With optimized conditions for Cu-mediated 18F-fluorodestannylation in hands the 
feasibility of the preparation of 18F-fluorinated aromatic amino acids from commercially 
available stannane precursors was evaluated. Using the novel radiolabeling protocol 
mono N-Boc protected SnMe3-substituted aromatic amino acid derivatives were 
successfully 18F-fluorinated although in low 5–6% RCY. Additional optimization of the 
radiolabeling conditions enabled to prepare 6-[18F]OMFD, 6-[18F]FDOPA, 2-[18F]F-Tyr 
and 6-[18F]FMT after subsequent deprotection in 9–16% RCYs in two steps. In contrast, 
N,N-di-Boc protected stannyl substrates were radiolabeled using the developed protocol 
affording after deprotection the desired PET tracers in 37-78% RCYs. These substrates 
were prepared in one step from the respective mono-N-Boc protected stannyl substituted 
amino esters. 
Finally, the implementation of the optimized procedure for Cu-mediated 18F-
fluorodestannylation on a synthesis module enabled the cGMP preparation of clinical 
doses of 6-[18F]OMFD, 6-[18F]FDOPA, 2-[18F]F-Tyr and 6-[18F]FMT in 32–57% RCY 
within 1 h. Especially, 6-[18F]FDOPA, the most widely used PET-tracer for 
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neuroimaging, was prepared in RCY of 57% which is far above the RCYs reported in the 
literature. 
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5 Experimental 
5.1 Synthesis of precursors and HPLC reference compounds 
5.1.1 General procedure 
All chemicals and solvents were used in synthesis were purchased from Sigma-Aldrich 
GmbH (Steinheim, Germany), Fluka AG (Buchs, Switzerland), TCI EUROPE N.V. 
(Zwijndrecht, Belgium), ChemPUR GmbH (Karlsruhe, Germany), Merck KGaA 
(Darmstadt, Germany) and ABCR GmbH (Karlsruhe, Germany) and used without special 
processing or purification. Dry solvents were purchased in sufficient purity from Sigma-
Aldrich GmbH (Steinheim, Germany) and were stored under argon. 
5.1.1.1 Nuclear magnetic resonance (NMR) 
1H-NMR spectra: Bruker DPX Avance 200 (200 MHz), Bruker Avance II 300 (300 MHz) 
and Varian INOVA 400 (400 MHz). 1H chemical shifts are reported in ppm relative to 
residual peaks of deuterated solvents. The observed signal multiplicities are characterized 
as follows: s = singlet, d = doublet, t = triplet, m = multiplet, and br = broad. Coupling 
constants (J) were reported in Hertz (Hz). 
13C-NMR spectra [additional APT (Attached Proton Test)]: Bruker DPX Avance 200 
(50 MHz), Bruker Avance II 300 (75 MHz) and Varian INOVA 400 (101 MHz). 13C 
chemical shifts are reported relative to residual peaks of deuterated solvents. 
19F-NMR spectra: Bruker DPX Avance 200 (188 MHz). 
5.1.1.2 Mass spectroscopy (MS) 
High-resolution mass spectrometry (HR-MS) were carried out on LTQ FT Ultra from 
Thermo Fisher Scientific Inc. (Bremen, Germany). The measuring mode was ESI positive 
(+) or negative ( ̶ ). 
Inductively coupled plasma mass spectrometry (ICP-MS) was carried out using Agilent 
7900 ICP-MS from Gilent Technologies, Santa Clara, United States. 
Low-resolution mass spectra were obtained in electrospray ionization (ESI) positive 
mode with a Thermo Finnigan Surveyor mass spectrometer (Thermo Fisher Scientific 
GmbH, Dreieich). 
5.1.1.3 Miscellaneous Information 
All moisture-sensitive or oxygen-sensitive reactions were carried out under atmosphere 
of argon. The reaction vessels used for this purpose were dried for at least 2 hours at 
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140 °C and purged with argon 5.0 (> 99.999%, Air Liquide GmbH) thrice using Schlenk 
line. Before introducing the protective gas into the apparatus, it is purified by a 
Hydrosorbpatrone from Linde AG (Pullach, Germany; Specification <20 ppb H2O 
residual impurity). The vacuum was achieved by a rotary pump RZ 6 (up to 4×10-4 mbar) 
of the company Vacuubrand GmbH (Wertheim, Germany). 
In column chromatography silica gel technical grade (w/Ca, ~0.1%), 60 Å, 230-400 mesh 
particle size, Ca 0.1-0.3% from Sigma-Aldrich GmbH (Steinheim, Germany) for the 
purification of aryl stannanes. Merck silica gel, grade 60, 230–400 mesh was used for 
other compounds. Solvent proportions are indicated in a volume/volume ratio. 
Thin layer chromatography (TLC) was performed using aluminum finish ALUGRAM® 
SIL G / UV254 from Macherey-Nagel GmbH (Düren, Germany) or Merck precoated 
sheets, 0.25 mm Sil G/UV254. The chromatograms were viewed under UV light 254 nm.  
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5.1.2 3-(Benzo[d][1,3]dioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole (1a) 
General procedure A: A solution of 9c (2.4 g, 6.91 mmol) and hydrazine monohydrate 
(1 mL, 98%, 13.83 mmol, 2 eq.) in ethanol (30 ml) was refluxed for 3 h. Water was added 
to the clear yellow solution and resulting precipitate was collected by filtration, washed 
with water and dried under vacuum to provide the title compound. 
Yield   2 g, 84% 
Appearance  white solid 
Molecular formula C16H11BrN2O2 
Molar mass  343.18000 
TLC   Rf = 0.31 (EtOAc/petroleum ether, 1:4) 
1H-NMR (200 MHz, DMSO-d6 + DCl): δ [ppm] = 7.97 (s, 1H), 7.79 (d, J = 
7.6 Hz, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.34 (t, J = 9.2 Hz, 4H), 6.89 
(d, J = 8.6 Hz, 1H), 5.96 (s, 2H). 
13C-NMR (50 MHz, DMSO-d6 + DCl): δ [ppm] = 148.94, 148.55, 147.18, 
146.64, 132.67, 131.93, 131.75, 129.01, 125.66, 123.08, 122.73, 
121.20, 109.56, 106.84, 102.31, 101.64, 12.33. 
HRMS m/z: [M + H]+ calcd for C16H12BrN2O2
+: 343.00767; found: 
343.00781. Correct isotopic pattern. 
5.1.3 5-(3-Bromophenyl)-3-(6-fluorobenzo[d][1,3]dioxol-5-yl)-1H-pyrazole (1b) 
Lithium tert-butoxide (214 mg, 2.7 mmol, 3 eq.) was added to 3b (300 mg, 0.9 mmol) at 
room temperature in toluene under argon and stirred for 15 min. After that, 2a (420 mg, 
2.3 mmol, 3 eq.) was added to the mixture and stirred for 48 h at 95 °C. The volatiles 
were removed under reduced pressure, and the residue was dissolved in EtOAc (50 mL) 
and washed with water (30×3 mL) and brine (30 mL). The combined organic phases were 
dried over MgSO4. After filtration and removal of the solvent under reduced pressure, the 
residue was purified by gravity chromatography. 
Yield   140 mg, 43% 
Appearance  white solid 
Molecular formula C16H10BrFN2O2 
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Molar mass  361.17040 
TLC   Rf = 0.30 (ethyl acetate/petroleum ether, 1:4) 
1H-NMR (200 MHz, DMSO-d6): δ [ppm] = 13.41 (s, 1H), 8.03 (s, 1H), 7.83 
(d, J = 7.1 Hz, 1H), 7.51 (d, J = 7.1 Hz, 1H), 7.39 (t, J = 6.1 Hz, 
2H), 7.06 (s, 2H), 6.11 (s, 2H). 
13C-NMR (50 MHz, DMSO-d6 + DCl): δ [ppm] = 156.62, 151.80, 148.12, 
147.83, 146.25, 144.27, 144.23, 141.37, 134.09, 131.28, 130.67, 
127.77, 124.42, 122.46, 111.31, 111.01, 106.13, 106.03, 102.56, 
102.36, 99.14, 98.53. 
19F-NMR  (188 MHz, DMSO-d6 + DCl): δ [ppm] = -119.92. 
HRMS m/z: [M + H]+ calcd for C16H11BrFN2O2
+: 360.99824; found: 
360.99823, Correct isotopic pattern. 
5.1.4 3-(Benzo[d][1,3]dioxol-5-yl)-5-(3-fluorophenyl)-1H-pyrazole (1c) 
The title compound was synthesized according to general procedure A using 9e (335 mg, 
1.17 mmol) and hydrazine monohydrate (1.3 eq.). 
Yield   735 mg, 84% 
Appearance  yellow solid 
Molecular formula C16H11FN2O2 
Molar mass  282.27440 
TLC   Rf = 0.32 (EtOAc/petroleum ether, 1:4) 
1H NMR (200 MHz, DMSO-d6 + DCl): δ [ppm] = 7.60 (s, 2H), 7.41 (d, J = 
6.4 Hz, 1H), 7.28 (d, J = 11.6 Hz, 3H), 7.14 (d, J = 8.7 Hz, 1H), 
6.85 (d, J = 8.3 Hz, 1H), 5.94 (s, 2H). 
13C NMR (50 MHz, DMSO-d6 + DCl): δ [ppm] = 165.50, 160.65, 148.95, 
148.50, 147.24, 146.84, 146.78, 131.98, 131.80, 131.59, 131.42, 
122.78, 122.61, 121.23, 113.53, 113.07, 109.48, 106.79, 102.28, 
101.65. 
19F NMR  (188 MHz, DMSO-d6 + DCl): δ [ppm] = -112.07. 
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HRMS m/z: [M + H]+ calcd for C16H12FN2O2
+: 283.08773; found: 
283.08775. 
5.1.5 3,5-bis(4-fluorophenyl)-1H-pyrazole (1d) 
4-fluorobenzaldehyde (100 µL, 0.94 mmol) was added to a solution of p-toluenesulfonyl 
hydrazide (193 mg, 1 mmol, 1.1 eq.). After the mixture was stirred for 1 h, a solution of 
NaOH (50 µL, 8M, 0.94 mmol, 1 eq.) was added and the mixture was stirred for a further 
20 min. Then 4´-fluorophenyl acetylene (540 µL, 4.7 mmol, 5 eq.) was added, and the 
mixture was stirred at 50 °C for 64 h. The volatiles were evaporated under reduced 
pressure, and the residue was taken with EtOAc (10 mL). The organic phase was washed 
with water (10 mL) and brine (10 mL) and dried over MgSO4. After removing the solvent 
under reduced pressure the title compound was obtained after recrystallized from Et2O/n-
pentane. 
Yield   40 mg, 17% 
Appearance  yellow solid 
Molecular formula C15H10F2N2 
Molar mass  256.25581 
TLC   Rf = 0.33 (petroleum ether/EtOAc, 3:1) 
1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 13.32 (s, 1H), 7.86 (dd, J = 8.7, 
5.5 Hz, 4H), 7.30 (t, J = 8.8 Hz, 4H), 7.16 (s, 1H). 
13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 163.86, 163.84, 160.62, 160.61, 
127.63, 127.52, 116.32, 116.03, 100.08. 
5.1.6 5-(3-Bromophenyl)-3-(6-iodobenzo[d][1,3]dioxol-5-yl)-1H-pyrazole (1e) 
In flame dried flask 4i (1 g, 3.62 mmol) and p-toluenesulfonyl hydrazide (0.681 g, 
3.66 mmol, 1.01 eq.) were stirred in anhydrous MeCN (50 mL) at 85 °C for 1 h. After 
that lithium tert-butoxide (7.25 mL, 1M in THF, 7.25 mmol, 2 eq.) was added to the 
mixture and stirred for 15 min. Then, 2a (1.312 g, 7.25 mmol, 2 eq.) was added to the 
mixture. After 24 h the reaction mixture was allowed to cool to room temperature, then 
MeCN was removed under reduced pressure, and the residue was dissolved in EtOAc 
(50 mL) and washed with water (3×80 mL) and brine (80 mL). The organic layer was 
separated and dried over MgSO4. After filtration and removal of the solvent, the crude 
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material was purified by gravity chromatography (twice: EtOAc:petroleum ether 1:4 and 
EtOAc:DCM 1:15) to deliver the title compound 
Yield   800 mg, 47% 
Appearance  white solid  
Molecular formula C16H10BrIN2O2 
Molar mass  469.07647 
TLC   Rf = 0.28 (EtOAc/petroleum ether, 1:4) 
   Rf = 0.48 (EtOAc/DCM, 1:15) 
1H-NMR (200 MHz, DMSO-d6 + DCl): δ [ppm] = 7.99 (s, 1H), 7.88 – 7.62 
(m, 2H), 7.42 (dd, J = 15.4, 7.9 Hz, 2H), 6.97 (dd, J = 16.9, 8.1 Hz, 
2H), 6.06 (s, 2H). 
13C-NMR (50 MHz, DMSO-d6 + DCl): δ [ppm] = 159.12, 154.26, 150.37, 
150.07, 144.64, 144.60, 143.79, 140.06, 139.95, 136.15, 130.17, 
129.91, 128.22, 127.48, 113.93, 113.70, 102.86, 102.82, 102.79, 
98.60, 98.00, 21.31, 21.21. 
HRMS m/z: [M + H]+ calcd for C16H11BrIN2O2
+: 468.90431; found: 
468.90467. Correct isotopic pattern. 
Another method was tried to synthesize the title compound. A solution of 9a (1.8 g, 
3.81 mmol) and hydrazine monohydrate (2 mL, 98%, 41.86 mmol, 11 eq.) in ethanol 
(20 ml) was refluxed for 3 h. Water was added to the clear yellow solution and resulting 
precipitate was collected by filtration, washed with water and dried to provide the title 
compound (1.2 g, 67%). 
5.1.7 tert-Butyl 5-(3-bromophenyl)-3-(6-iodobenzo[d][1,3]dioxol-5-yl)-1H-pyrazole-
1-carboxylate (1f) 
1e (200 mg, 0.4 mmol) was stirred with di-tert-butyl dicarbonate (200 mg, 0.9 mmol, 
2.2 eq.) and 4-dimethylaminopyridine (15.6 mg, 0.12 mmol, 0.3 eq) in THF (5 mL) at 
ambient temperature for 2 h. After that the reaction mixture was diluted with EtOAc 
(10 mL) and washed with water (3×5 mL) and brine (5 mL) then dried over MgSO4. After 
removing the solvents under reduced pressure, the residue was purified with flash 
chromatography. 
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Yield   210 mg, 89% 
Appearance  white solid 
Molecular formula C21H18BrIN2O4 
Molar mass  569.19347 
TLC   Rf = 0.30 (Et2O/petroleum ether, 1:4) 
1H-NMR (200 MHz, DMSO-d6): δ [ppm] = 8.12 (s, 1H), 7.95 (d, J = 7.9 Hz, 
1H), 7.63 (d, J = 8.8 Hz, 1H), 7.51 (d, J = 4.8 Hz, 1H), 7.43 (d, J = 
7.8 Hz, 1H), 7.10 (d, J = 2.9 Hz, 2H), 6.12 (s, 2H), 1.32 (s, 9H). 
13C-NMR (50 MHz, DMSO-d6): δ [ppm] = 150.97, 148.60, 147.94, 147.68, 
146.63, 146.21, 133.79, 131.78, 131.12, 130.45, 128.28, 124.87, 
122.31, 117.48, 110.49, 108.96, 102.11, 89.45, 85.57, 85.00, 84.35, 
26.86. 
HRMS m/z: [M + H]+ calcd for C21H19BrIN2O4
+: 568.95674; found: 
568.95783. Correct isotopic pattern. 
5.1.8 5-(3-Bromophenyl)-3-(6-iodobenzo[d][1,3]dioxol-5-yl)-1-tosyl-1H-pyrazole 
(1g) 
1e (170 mg, 0.36 mmol, 1 eq.) was stirred with NaH (26 mg, 1 mmol, 3 eq.) in anhydrous 
THF (5 mL) at 0 °C. Then 4-methylbenzenesulfonyl chloride (207 mg, 1 mmol, 3 eq.) 
was added. After 24 h that the reaction mixture was diluted with EtOAc (10 mL) and 
washed with water (3×5 mL) and brine (5 mL) then dried over MgSO4. After removing 
the solvents under reduced pressure, the residue was purified with flash chromatography 
(EtOAc/petroleum ether, 1:9). 
Yield   175 mg, 77% 
Appearance  White solid 
Molecular formula C23H16BrIN2O4S 
Molar mass  623.25947 
1H NMR (200 MHz, CDCl3): δ [ppm] = 8.06 (t, J = 1.6 Hz, 1H), 7.99 – 7.66 
(m, 3H), 7.65 – 7.45 (m, 1H), 7.33 (d, J = 7.7 Hz, 4H), 6.87 (s, 1H), 
6.62 (s, 1H), 6.11 (d, J = 3.2 Hz, 2H), 2.44 (s, 3H). 
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13C NMR (50 MHz, CDCl3): δ [ppm] = 152.79, 149.51, 149.07, 147.91, 
145.85, 134.56, 133.50, 132.14, 130.29, 129.90, 129.33, 128.76, 
127.92, 125.04, 122.92, 118.32, 111.48, 109.60, 102.31, 88.99, 
21.83. 
HRMS m/z: [M + H]+ calcd for C23H17BrIN2O4S
+: 622.91316; found: 
622.91365. Correct isotopic pattern. 
5.1.9 tert-Butyl 3-(benzo[d][1,3]dioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole-1-
carboxylate (1j) 
1a (1.9 g, 5.5 mmol, 1 eq.) was stirred with di-tert-butyl dicarbonate (2.54 g, 11.6 mmol, 
2.1 eq.) and 4-dimethylaminopyridine (0.2 mg, 1.7 mmol, 0.3 eq) in THF (5 mL) at 
ambient temperature for 18 h. After removing THF under vacuum the residue was 
purified with flash chromatography. 
Yield   2.2 g, 90% 
Appearance  white solid 
Molecular formula C21H19BrN2O4 
Molar mass  443.29700 
TLC   Rf = 0.35 (Et2O/petroleum ether, 1:4) 
1H-NMR (200 MHz, DMSO-d6) δ 8.08 (d, J = 1.6 Hz, 1H), 7.92 (d, J = 
7.8 Hz, 1H), 7.75 – 7.52 (m, 1H), 7.43 (t, J = 7.9 Hz, 1H), 7.24 – 
7.05 (m, 2H), 7.00 (d, J = 7.9 Hz, 1H), 6.93 (dd, J = 8.0, 1.6 Hz, 
1H), 6.08 (s, 2H), 1.36 (s, 9H). 
13C-NMR (50 MHz, DMSO-d6): δ [ppm] = 150.92, 147.69, 147.39, 147.09, 
146.93, 133.98, 131.75, 131.14, 128.37, 124.94, 124.68, 122.87, 
122.32, 109.73, 108.64, 107.91, 101.40, 84.79, 27.15, 11.58. 
HRMS m/z: [M + H]+ calcd for C21H20BrN2O4
+: 443.06009; found: 
443.06089. Correct isotopic pattern. 
5.1.10 3-(Benzo[d][1,3]dioxol-5-yl)-5-(3-(trimethylstannyl)phenyl)-1H-pyrazole (1i) 
General procedure B: In flame dried flask 1a (550 mg, 1.6 mmol), Pd(PPh3)4 (185 mg, 
0.16 mmol, 0.1 eq.) were purged thrice with argon using Schlenck line technique. 
Anhydrous 1,4-dioxane (2 mL) was bubbled with a stream of argon for 30 min, then it 
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was added to the reagents at room temperature. Hexamethylditin (830 µL, 4 mmol, 
2.5 eq.) was added via syringe, and the mixture was heated to 100 °C for 18 h. The 
mixture was filtered through a plug of Celite and TBAF (2 mL, 1M in THF) was added to 
the filtrate, and the mixture was stirred for 30 min. The filtrate was washed with water 
(50 mL) and with brine (50 mL). After drying the solution over magnesium sulfate, it was 
concentrated under vacuum. The crude product was purified via flash column 
chromatography. The resulted yellow oil was recrystallized from DCM/Hexane (DCM 
was removed under reduced pressure). 
Yield   566 mg, 83% 
Appearance  white solid 
Molecular formula C19H20N2O2Sn 
Molar mass  427.09100 
TLC   Rf = 0.30 (EtOAc/petroleum ether, 1:4) 
1H-NMR (200 MHz, DMSO-d6): δ [ppm] =13.20 (s, 1H), 7.93 (s, 1H), 7.74 
(s, 1H), 7.60 – 7.22 (m, 5H), 7.12 (s, 1H), 6.99 (d, J = 7.7 Hz, 1H), 
6.06 (s, 2H), 0.31 (s, 9H). 
13C-NMR (50 MHz, DMSO-d6): δ [ppm] = 147.74, 146.86, 132.25, 128.28, 
125.03, 118.82, 108.59, 105.60, 101.12, 99.30, -9.29.  
HRMS m/z: [M + H]+ calcd for C19H21N2O2Sn
+: 429.06195; found: 
429.06286. Correct isotopic pattern. 
5.1.11 1-Bromo-3-ethynylbenzene (2a)90 
8 (35 g, 90.5 mmol) and K2CO3 (37.5 g, 271 mmol, 3 eq.) in DMSO (200 mL) was stirred 
at 115 °C for 18 h. After being cooled to ambient temperature, water was added to the 
heterogeneous mixture till it turned homogeneous. Then it was extracted using Et2O 
(3×150 mL). The organic layers were combined, rinsed with brine, and dried over 
MgSO4. Removals of solvent afford the title compound (10 g, 61%) as yellow oil. 
If pentane was used instead of Et2O and the resulted residue was 
purified over flash chromatography (pentane 100%), the product was 
obtained as colorless oil (8.5 g, 52%). 
Yield   8.5 g, 52% 
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Appearance  colorless oil turned yellow after two months at 5 °C 
Molecular formula C8H5Br  
Molar mass  181.03200 
TLC   Rf = 0.5 (pentane) 
1H-NMR (200 MHz, CDCl3): δ [ppm] = 7.64 (t, 1H), 7.44 (m, 2H), 7.20 (t, 
1H), 3.12 (s, 1H). 
5.1.12 N'-((6-Fluorobenzo[d][1,3]dioxol-5-yl)methylene)-4-
methylbenzenesulfonohydrazide (3b) 
General procedure C: 4c (300 mg, 1.8 mmol) was stirred at room temperature with p-
toluenesulfonyl hydrazide (400 mg, 2.1 mmol, 1.2 eq.) in MeOH (10 mL) for 4 h. The 
resulted precipitate was filtered and dried under vacuum to afford the title compound. 
Yield   400 mg, 67% 
Appearance  white solid 
Molecular formula C15H13FN2O4S 
Molar mass  336.33740 
1H-NMR (200 MHz, DMSO-d6): δ [ppm] = 11.42 (s, 1H), 7.96 (s, 1H), 7.76 
(d, J = 8.2 Hz, 2H), 7.40 (d, J = 8.0 Hz, 2H), 7.04 (d, J = 5.9 Hz, 
1H), 6.98 (d, J = 10.3 Hz, 1H), 6.09 (s, 2H), 2.36 (s, 3H). 
13C-NMR (50 MHz, DMSO-d6): δ [ppm] = 149.66, 149.37, 143.92, 142.94, 
139.56, 139.45, 135.85, 129.02, 126.93, 102.86, 101.85, 97.43, 
96.85, 20.96. 
19F-NMR  (188 MHz, DMSO-d6): δ [ppm] = -126.43. 
HRMS m/z: [M + H]+ calcd for C15H14FN2O4S
+: 337.06528; 
found:337.06535. 
5.1.13 N'-((6-Iodobenzo[d][1,3]dioxol-5-yl)methylene)-4-
methylbenzenesulfonohydrazide (3c) 
The title compound was synthesized according to general procedure C using 4i (1.8 g, 
6.5 mmol). 
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Yield   2.65 g, 91% 
Appearance  white solid 
Molecular formula C15H13IN2O4S 
Molar mass  444.24347 
1H-NMR (200 MHz, DMSO-d6): δ [ppm] = 11.54 (s, 1H), 8.02 (s, 1H), 7.76 
(d, J = 8.3 Hz, 2H), 7.41 (d, J = 7.0 Hz, 2H), 7.11 (s, 1H), 6.09 (s, 
2H), 2.36 (s, 3H). 
13C-NMR (101 MHz, CDCl3): δ [ppm] = 150.64, 148.96, 144.55, 129.90, 
128.74, 128.15, 119.61, 118.68, 109.07, 107.15, 102.82, 102.29, 
21.78. 
HRMS m/z: [M + H]+ calcd for C15H14IN2O4S
+: 444.97135; found: 
444.97144. 
Anal. Calcd for C15H13IN2O4S: C, 40.56; H, 2.95; N, 6.31; Found: 
C, 39,79±0.26; H, 2.94±0.02; N, 6.55±0.04. 
5.1.14 4-Methyl-N'-((6-(trimethylstannyl)benzo[d][1,3]dioxol-5-
yl)methylene)benzenesulfonohydrazide (3d) 
The title compound was synthesized according to general procedure C using 4l (400 mg, 
1.3 mmol) and stirred for 18 h. After that MeOH was removed under vacuum and the 
residue was purified with flash chromatography EtOAc:petroleum ether (1:4). 
Yield   170 mg, 28% 
Appearance  yellow oil 
Molecular formula C18H22N2O4SSn 
Molar mass  481.15400 
1H NMR (200 MHz, DMSO-d6): δ [ppm] = 11.45 (s, 1H), 7.93 (s, 1H), 7.72 
(d, J = 8.3 Hz, 2H), 7.40 (d, J = 8.0 Hz, 2H), 7.11 (s, 1H), 6.92 (s, 
1H), 6.02 (s, 2H), 2.35 (s, 3H), 0.17 (s, 9H). 
13C NMR  (50 MHz, DMSO-d6): δ [ppm] = 149.07, 148.66, 148.14, 143.42, 
136.39, 135.91, 133.51, 129.72, 127.12, 115.15, 108.12, 101.23, 
21.00, -7.12. 
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HRMS m/z: [M – CH3]+ calcd for C17H19N2O4SSn+: 467.00820; found: 
467.00877. Correct isotopic pattern. 
5.1.15 4-Methyl-N'-((6-nitrobenzo[d][1,3]dioxol-5-
yl)methylene)benzenesulfonohydrazide (3f) 
The title compound was synthesized according to general procedure C using 6-
nitropiperonal (1.8 g, 6.5 mmol). 
Yield   2.65 g, 91% 
Appearance  yellow solid  
Molecular formula C15H13N3O6S 
Molar mass  363.34400 
1H-NMR (200 MHz, DMSO-d6): δ [ppm] = 11.92 (s, 1H), 8.38 (s, 1H), 7.88 
(d, J = 8.2 Hz, 2H), 7.71 (s, 1H), 7.52 (d, J = 8.0 Hz, 2H), 7.25 (s, 
1H), 6.36 (s, 2H), 2.47 (s, 3H). 
13C-NMR (50 MHz, DMSO-d6): δ [ppm] = 151.78, 148.93, 143.67, 142.80, 
142.42, 136.02, 129.79, 127.22, 125.02, 104.95, 103.86, 21.02. 
HRMS m/z: [M + H]+ calcd for C15H14N3O6S
+: 364.05978; found: 
364.05989. 
5.1.16 6-Fluorobenzo[d][1,3]dioxole-5-carbaldehyde (4c)76 
In flame dried flask under inert atmosphere of argon 6-fluoroveratraldehyde (1 g, 
5.4 mmol) was dissolved in anhydrous DCM (10 mL). The mixture was placed in acetone 
and dry ice bath (-80 °C), then BBr3 (10 mL of a 1M solution in DCM) was added 
dropwise. The reaction mixture was allowed to warm to room temperature and stirred for 
18 h. After that, methanol was added to the resulting mixture at -80 °C, and stirred at 
ambient temperature for 1 h. Then solvents were removed. This process was repeated 
three times. The residue was purified with column chromatography (DCM/EtOAc, 5:1) 
to afford 2-fluoro-4,5-dihydroxybenzaldehyde (700 mg, 83%) as yellow solid Rf = 0.33 
(DCM/EtOAc, 5:1). This compound is directly used in the next step. 
In flame dried flask under inert atmosphere of argon bromochloromethane (680 mg, 
5.3 mmol, 1.5 eq.) was added to a stirred suspension of 2-fluoro-4,5-
dihydroxybenzaldehyde (550 mg, 3.5 mmol) and cesium carbonate (2.65 g, 10.6 mmol, 
E x p e r i m e n t a l   P a g e  | 56 
 
 
3 eq.) in anhydrous DMF (20 mL). The resulting mixture was heated at 110 °C for 18 h. 
After cooling to room temperature, water (50 mL) was added and the aqueous layer was 
extracted with EtOAc (3×50 mL). The organic layers were combined, washed with water, 
brine and dried over MgSO4. Evaporation of the solvents left a residue, which was 
purified by flash column chromatography petroleum ether:Et2O (3:1). 
Yield   450 mg, 76% 
Appearance  white solid 
Molecular formula C8H5FO3 
Molar mass  168.12340 
1H-NMR (200 MHz, CDCl3): δ [ppm] = 10.17 (s, 1H), 7.21 (d, J = 5.6 Hz, 
1H), 6.63 (d, J = 9.7 Hz, 1H)., 6.07 (s, 2H). 
13C-NMR (50 MHz, CDCl3): δ [ppm] = 185.58, 162.71, 154.16, 144.97, 
118.02, 105.11, 103.00, 98.09. 
19F-NMR (188 MHz, CDCl3): δ [ppm] = -126.08. 
5.1.17 6-(Dimethylamino)benzo[d][1,3]dioxole-5-carbaldehyde (4d) 
4c (1 g, 5.9 mmol), dimethylaminehydrochloride (0.63 g, 7.7 mmol, 1.3 eq.) and 
potassium carbonate (1.07 g, 7.7 mmol, 1.3 eq.) were stirred and heated to reflux (130 °C) 
in a mixture of DMSO (10 ml) and water (4 ml). Saturated aqueous potassium carbonate 
(20 ml) was added to the cooled solution, which was twice extracted with Et2O (30 mL). 
The combined organic phases were washed with brine (50 mL) dried on MgSO4. The 
yellow oil obtained after filtration and evaporation was purified with flash 
chromatography to deliver the title compound. 
Yield   780 mg, 68% 
Appearance  yellow solid 
Molecular formula C10H11NO3 
Molar mass  193.20200 
TLC   Rf = 0.30 (Et2O/petroleum ether, 1:4) 
1H-NMR (200 MHz, CDCl3): δ [ppm] = 10.15 (s, 1H), 7.23 (s, 1H), 6.63 (s, 
1H), 5.97 (s, 2H), 2.83 (s, 6H). 
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13C-NMR (50 MHz, CDCl3): δ [ppm] = 189.74, 153.50, 122.43, 107.44, 
101.93, 99.80, 46.65. 
HRMS m/z: [M + H]+ calcd for C10H12NO3
+: 194.08117; found: 
194.08204. 
5.1.18 6-Aminobenzo[d][1,3]dioxole-5-carbaldehyde (4f)91 
To 6-nitropiperonal (3.5 g, 17.9 mmol) dissolved in EtOH/H2O (3:1, 150 mL) iron 
powder (10 g, 179.4 mmol, 10 eq.) and HCl (38%, 100 µL) was added. The mixture was 
stirred at 70 °C for 3 h. after cooling to room temperature the mixture was filtered over 
Celite and the filtrate was dried under reduced pressure. The residue was dissolved in 
DCM and dried over MgSO4. Then DCM was removed to deliver the title compound. 
Yield   2.6 g, 88% 
Appearance  yellow solid 
Molecular formula C8H7NO3 
Molar mass  165.14800 
1H-NMR (200 MHz, CDCl3): δ [ppm] = 9.61 (s, 1H), 6.82 (s, 1H), 6.36 (br, 
2H), 6.14 (s, 1H), 5.93 (s, 2H). 
5.1.19 6-Iodobenzo[d][1,3]dioxole-5-carbaldehyde (4i) 
To a solution of (6-iodobenzo[d][1,3]dioxol-5-yl)methanol (2 g, 7.2 mmol) in anhydrous 
DCM (50 mL) at 0 ºC under argon pyridinium chlorochromate (3.1 g, 14.4 mmol, 2 eq.) 
was added portionwise. The resulting mixture stirred at ambient temperature for 18 h. 
After this time, the solids were removed by filtration over a plug of silica that was 
subsequently washed with DCM (50 mL). The combined filtrates were concentrated 
under reduced pressure to afford a pale-yellow oil that was purified by column 
chromatography to provide the title compound. 
Yield   1.88 g, 95% 
Appearance  off-white solid  
Molecular formula C8H5IO3 
Molar mass  276.02947 
TLC   Rf = 0.72 (DCM) 
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1H-NMR (200 MHz, CDCl3): δ [ppm] = 9.88 (s, 1H), 7.37 (s, 1H), 7.33 (s, 
1H), 6.08 (s, 2H). 
Another method was tried to synthesize the title compound.92 To a solution of (6-
formylbenzo[d][1,3]dioxol-5-yl)boronic acid (240 mg, 1.2 mmol) in dry acetonitrile 
(10 mL) N-iodosuccinimide (418 mg, 1.9 mmol, 1.5 eq.) was added and the mixture was 
stirred at 80 °C for 18 h in darkness. After that, the reaction mixture was extracted thrice 
with petroleum ether (50 mL) and the combined extracts were washed with aqueous 
NaHCO3 (5%, 50 mL), distilled water, brine and finally dried over MgSO4. The residue 
obtained by evaporation of the solvent was purified by column chromatography. The 
spectroscopic data of the product matched to those of the first method. Yield (285 mg, 
83%). 
5.1.20 6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d][1,3]dioxole-5-
carbaldehyde (4j) 
(6-Formylbenzo[d][1,3]dioxol-5-yl)boronic acid (0.5 g, 2.58 mmol) and pinacol (347 µL, 
2.84 mmol, 1.1 eq.) was refluxed in toluene (10 mL) for 18 h. After cooling, the mixture 
was filtered through a pad of Celite and a pad of Na2SO4. The solvent was then removed 
in vacuum by adding MeOH (2×10 mL) to remove toluene. The residue was recrystallized 
from petroleum ether to yield the title compound. 
Yield   500 mg, 70% 
Appearance  white solid 
Molecular formula C14H17BO5 
Molar mass  276.0950 
1H-NMR93 (400 MHz, CDCl3): δ [ppm] = 10.50 (s, 1H), 7.46 (s, 1H), 7.31 (s, 
1H), 6.04 (s, 1H), 1.36 (s, 12H). 
13C-NMR (101 MHz, CDCl3) δ [ppm] = 193.00, 151.88, 150.47, 138.28, 
114.89, 106.84, 102.03, 84.54, 24.98. 
HRMS m/z: [M + H]+ calcd for C14H18BO5
+: 277.12418; found: 
277.12432. 
Anal. Calcd for C14H17BO5: C, 60.90; H, 6.21. Found: C, 60.88 ± 0.02; 
H, 6.25± < 0.01. 
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5.1.21 Potassium trifluoro(6-formylbenzo[d][1,3]dioxol-5-yl)borate (4k) 
(6-Formylbenzo[d][1,3]dioxol-5-yl)boronic acid (200 mg, 1 mmol) was stirred with 
potassium bifluoride (240 mg, 3.1 mmol, 3 eq.) in a mixture of MeOH (4 ml) and water 
(2 ml) for 2 h at ambient temperature. After that, the solvents were removed under 
reduced pressure. Acetonitrile was added to the residue and treated in ultrasonic bath then 
acetonitrile was removed and this process was repeated three times. The acetonitrile 
phases were combined and dried under reduced pressure to deliver the title compound. 
Yield   220 mg, 83% 
Appearance  white solid 
Molecular formula C8H5BF3KO3 
Molar mass  256.02851 
1H-NMR (200 MHz, DMSO-d6): δ [ppm] = 10.24 (s, 1H, H-8), 7.14 (s, 1H, 
H-), 7.01 (s, 1H, H-), 5.99 (s, 2H, H-1). 
19F-NMR  (188 MHz, DMSO-d6): δ [ppm] = -131.83. 
HRMS   m/z: [M - K]- calcd for C8H5BF3O3
-: 217.02893; found: 217.02878. 
5.1.22 6-(Trimethylstannyl)benzo[d][1,3]dioxole-5-carbaldehyde (4l) 
The title compound was synthesized according to general procedure B using methyl 6-
bromopiperonal (2.95 g, 13 mmol), Pd(PPh3)4 (0.05 eq.) and hexamethylditin (1.2 eq.). 
The crude mixture was purified with flash chromatography petroleum ether:Et2O (4:1). 
Yield   3 g, 74% 
Appearance  white solid 
Molecular formula C11H14O3Sn 
Molar mass  312.94000 
1H NMR (200 MHz, CDCl3): δ [ppm] = 9.77 (d, J = 0.7 Hz, 1H), 7.31 (dd, J 
= 9.7, 4.1 Hz, 1H), 7.22 – 7.14 (m, 1H), 6.07 (s, 2H), 0.27 (s, 9H). 
13C NMR (50 MHz, CDCl3): δ [ppm] = 191.43, 152.53, 148.57, 141.77, 
135.77, 116.41, 114.01, 101.90, -7.55. 
HRMS m/z: [M – CH3]+ calcd for C10H11O3Sn+: 298.97247; found: 
298.97264. Correct isotopic pattern. 
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5.1.23 1-(Benzo[d][1,3]dioxol-5-yl)ethan-1-ol (5a) 
General procedure D: To a stirred solution of a piperonal (3 g, 20 mmol) in dry THF 
(60 mL) methylmagnesium bromide (20 mL of a 3M solution in Et2O, 3.0 eq.) was added 
at 0 °C. The reaction mixture was stirred at 0 °C for 30 min and then warmed to room 
temperature. After stirring overnight, saturated aqueous NH4Cl (40 mL) was added 
slowly at 0 °C and then extracted with ethyl acetate (3×40 mL). The combined organic 
phases was dried over MgSO4. Evaporation of the solvent and purification by column 
chromatography (EtOAc:petroleum ether, 1:4) afforded the pure product. 
Yield   3.1 g, 93% 
Appearance  yellow oil 
Molecular formula C9H10O3 
Molar mass  166.17600 
1H NMR (200 MHz, CDCl3): δ [ppm] = 6.88 (d, J = 1.0 Hz, 1H), 6.81 (t, J = 
4.8 Hz, 1H), 6.76 (d, J = 7.9 Hz, 1H), 5.94 (d, J = 0.4 Hz, 2H), 4.80 
(q, J = 6.5 Hz, 1H), 2.03 (s, 1H), 1.45 (d, J = 6.4 Hz, 3H). 
13C NMR (50 MHz, CDCl3): δ [ppm] = 147.78, 146.84, 140.05, 118.72, 
108.11, 106.09, 101.00, 70.23, 25.17. 
5.1.24 1-(6-Iodobenzo[d][1,3]dioxol-5-yl)ethan-1-ol (5b) 
In a darkened fume hood, a solution of molecular iodine (5.10 g, 20 mmol, 1.2 eq.) in 
MeOH (50 mL) was added, dropwise and via a pressure-equalized dropping funnel, to a 
magnetically stirred suspension of 5a (2.8 g, 16.8 mmol) and silver trifluoroacetate (4.46 
g, 20 mmol, 1.2 eq.) in CHCl3 (50 mL) maintained at 0 ºC under argon. The resulting 
suspension was stirred vigorously at ambient temperature for 18 h. The solids formed 
were removed by filtration through a pad of Celite. The pad was washed with CHCl3 (50 
mL), the combined filtrates concentrated under reduced pressure, and the dark-red residue 
thus obtained was dissolved in DCM (100 mL) and the solution was washed three times 
with saturated aqueous solution of sodium thiosulfate (50 mL) then brine (50 mL) before 
being dried over MgSO4, filtered and concentrated under reduced pressure. The residue 
was purified with flash chromatography (DCM) to provide the title compound. 
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Yield   2.5 g, 51% 
Appearance  off white solid  
Molecular formula C9H9IO3 
Molar mass  292.07247 
1H NMR (200 MHz, CDCl3): δ [ppm] = 7.20 (s, 1H), 7.09 (s, 1H), 5.97 (dd, 
J = 3.3, 1.4 Hz, 2H), 5.01 (q, J = 6.3 Hz, 1H), 1.99 (s, 1H), 1.40 (d, 
J = 6.3 Hz, 3H). 
13C NMR (50 MHz, CDCl3): δ [ppm] = 148.92, 147.75, 141.20, 118.33, 
106.64, 101.69, 84.62, 73.75, 23.84. 
5.1.25 1-(6-Bromobenzo[d][1,3]dioxol-5-yl)ethan-1-ol (5c)94 
The title compound was synthesized according to general procedure D using 6-
bromopiperonal (2 g, 9 mmol). Then it was purified by flash chromatography 
(EtOAc:petroleum ether, 1:4) afforded the pure product. 
Yield   1.5 mg, 69% 
Appearance  colorless oil 
Molecular formula C9H9BrO3 
Molar mass  245.07200 
1H-NMR (200 MHz, CDCl3): δ [ppm] = 7.09 (s, 1H), 6.96 (s, 1H), 5.97 (dd, 
J = 2.8, 1.4 Hz, 2H), 5.17 (q, J = 6.2 Hz, 1H), 1.91 (s, 1H), 1.43 (d, 
J = 6.4 Hz, 3H). 
13C-NMR (50 MHz, CDCl3): δ [ppm] = 147.93, 147.58, 138.24, 112.57, 
111.91, 106.78, 101.85, 69.23, 23.77. 
5.1.26 1-(6-Iodobenzo[d][1,3]dioxol-5-yl)ethan-1-one (6a) 
To a solution of 5b (2 g, 6.8 mmol) in anhydrous DCM (50 mL) at 0 ºC under argon 
pyridinium chlorochromate (2.9 g, 13.7 mmol, 2 eq.) was added portionwise. The 
resulting mixture stirred at ambient temperature for 18 h. After this time, the solids were 
removed by passing the reaction mixture through a plug of silica that was subsequently 
washed with DCM (50 mL). The combined filtrates were concentrated under reduced 
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pressure to afford pale-yellow oil that was purified by flash chromatography (DCM) to 
provide the title compound. 
Yield   1.8 g, 91% 
Appearance  yellow solid  
Molecular formula C9H7IO3 
Molar mass  290.05647 
1H NMR (200 MHz, CDCl3): δ [ppm] = 7.36 (s, 1H), 7.05 (s, 1H), 6.04 (s, 
2H), 2.58 (s, 3H). 
13C NMR (50 MHz, CDCl3): δ [ppm] = 199.63, 150.40, 148.27, 136.63, 
120.71, 109.23, 102.39, 81.42, 29.29. 
5.1.27 1-(6-Bromobenzo[d][1,3]dioxol-5-yl)ethan-1-one (6b) 
To a solution of 5c (1.4 g, 6 mmol) in dry DCM (50 mL) at 0 °C pyridinium 
chlorochromate (2.6 g, 12 mmol, 2 eq.) was added. The mixture was stirred for 2 h and 
then allowed to warm to room temperature and stirred overnight. The resulted mixture 
was filtered through silica. DCM was removed under vacuum to deliver the title 
compound after recrystallization from DCM/hexane. 
Yield   1.5 g, 69% 
Appearance  White solid 
Molecular formula C9H7BrO3  
Molar mass  243.05600 
1H-NMR94 (200 MHz, CDCl3): δ [ppm] = 7.08 – 6.97 (m, 2H)., 6.03 (s, 2H), 
2.60 (s, 3H). 
13C-NMR (50 MHz, CDCl3) δ 199.65, 150.50, 147.52, 134.42, 114.02, 
112.10, 109.47, 102.56, 30.44. 
5.1.28 1-(6-(Trimethylstannyl)benzo[d][1,3]dioxol-5-yl)ethan-1-one (6c) 
The title compound was synthesized according to general procedure B using 6b (1.2 g, 
5.1 mmol), Pd(PPh3)4 (295 mg, 0.3 mmol, 0.05 eq.) and hexamethylditin (1.2 mL, 
6.1 mmol, 1.2 eq.). The product was purified with flash chromatography (Et2O:petroleum 
ether, 1:9). 
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Yield   450 mg, 27% 
Appearance  white solid 
Molecular formula C12H16O3Sn  
Molar mass  326.96700 
1H-NMR (200 MHz, CDCl3): δ [ppm] = 7.48 (s, 1H), 7.17 (s, 1H), 6.05 (s, 
2H), 2.57 (s, 3H), 0.20 (s, 9H). 
13C-NMR (50 MHz, CDCl3): δ [ppm] = 197.43, 151.73, 148.26, 142.63, 
135.34, 116.02, 110.75, 101.86, 26.45, -6.97. 
HRMS m/z: [M – CH3]+ calcd for C11H13O3Sn+: 312.98812; found: 
312.98846. Correct isotopic pattern. 
5.1.29 Methyl 3,4-(methylenedioxy)-6-nitrophenyl ketone (6d) 
To 3,4-(methylenedioxy)-acetophenone (0.5 g, 3 mmol) in MeNO2 (10 mL) at ambient 
temperature was added HNO3 (1 mL, 65%, 18.3 mmol, 6 eq.) dropwise in 10 min. The 
solution was stirred for additional 2 h. The reaction mixture was carefully neutralized by 
the addition of saturated aqueous NaHCO3 solution and then extracted with DCM. The 
combined organic phase was dried over Na2SO4. The solvent was removed in vacuum 
and the residue was purified by flash chromatography to afford the title compound. 
Yield   250 mg, 39% 
Appearance  yellow solid 
Molecular formula C9H7NO5 
Molar mass  209.15700 
TLC   Rf = 0.48 (EtOAc:petroleum ether 1:2) 
1H NMR (200 MHz, CDCl3): δ [ppm] = 7.51 (s, 1H), 6.73 (s, 1H), 6.17 (s, 
2H), 2.47 (s, 3H). 
13C NMR (50 MHz, CDCl3): δ [ppm] = 199.33, 152.83, 148.97, 135.23, 
106.29, 104.91, 103.78, 30.32. 
5.1.30 1-Bromo-3-(2',2'-dibromovinyl)benzene (7) 
3-Bromobenzaldehyde (630 µL, 5.4 mmol,) was added to a reagent prepared from 
interaction of zinc dust (0.7 g, 10.8 mmol, 2 eq.), triphenylphosphine (2.8 g, 10.8 mmol, 
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2 eq.), and tetrabromomethane (3.6 g, 10.8 mmol, 2 eq.) in DCM at room temperature for 
30 h with a reaction time of 12 h at room temperature. After that DCM was evaporated 
and the rest was taken with Et2O (100 mL), washed with water (2×100 mL) and brine 
(100 mL) and then dried over MgSO4. The organic phase was dried under vacuum and 
the raw product was purified by column chromatography (petroleum ether) to give the 
desired product. 
Yield   1.8 g, 98% 
Appearance  yellow oil 
Molecular formula C8H5Br3 
Molar mass  340.84000 
1H NMR (200 MHz, CDCl3): δ [ppm] = 8.23 – 6.01 (m, 5H). 
5.1.31 2,3-Dibromo-3-(3-bromophenyl)propanoic acid (8)95 
Sodium bromide (27.2 g, 264 mmol, 2.4 eq.) is added to mixture of sodium perborate 
tetrahydrate (20.3 g, 132 mmol, 1.2 eq.) and 3-bromocinnamic acid (25 g, 110 mmol) in 
glacial acetic acid (200 mL) and stirred for 18 h at room temperature. The mixture is then 
diluted with water, the product extracted into ether and dried over MgSO4. Removals of 
solvent afford the title compound. 
Yield   35 g, 82% 
Appearance  white solid 
Molecular formula C9H7Br3O2 
Molar mass  386.86500 
1H-NMR (200 MHz, DMSO-d6): δ [ppm] = 7.93 (t, J = 1.6 Hz, 1H), 7.66 (d, 
J = 7.9 Hz, 1H), 7.54 (ddd, J = 8.0, 1.9, 1.0 Hz, 1H), 7.42 – 7.20 
(m, 1H), 5.57 (d, J = 11.8 Hz, 1H), 5.38 (d, J = 11.8 Hz, 1H), 4.30 
(br, 1H). 
13C-NMR (50 MHz, DMSO-d6): δ [ppm] = 168.98, 140.99, 131.93, 131.17, 
130.83, 127.56, 121.75, 50.27, 46.81. 
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5.1.32 1-(3-Bromophenyl)-3-hydroxy-3-(6-iodobenzo[d][1,3]dioxol-5-yl)prop-2-en-1-
one (9a) 
General procedure E: To a solution of 6a (1.5 g, 5.2 mmol) in anhydrous THF (20 mL) 
was added LiHMDS (15.6 mL, 1M in THF, 15.6 mmol, 3 eq.) and the resulting solution 
stirred for 1 h at -80 °C. The solution was warmed to room temperature and stirred for 
2 h before cooling to -80 °C and adding 3-bromobenzoyl chloride (0.68 mL, 5.2 mmol, 
1 eq.) dropwise. The solution was allowed to warm to room temperature and stirred for 
additional 18 h. Then the reaction was quenched with saturated solution of NH4Cl 
(50 mL). The pH adjusted to 7.0. Then extracted with EtOAc (3×50 mL). The combined 
organic layers were washed with brine (100 mL), dried over MgSO4 and then dried under 
vacuum. The resulted residue was purified with flash chromatography. 
Yield   2 g, 84% 
Appearance  yellow solid  
Molecular formula C16H10BrIO4 
Molar mass  473.06047 
TLC   Rf = 0.53 (Et2O/petroleum ether, 1:4) 
1H NMR (200 MHz, CDCl3): δ [ppm] = 16.04 (s, 1H), 8.06 (t, J = 1.7 Hz, 
1H), 7.96 – 7.75 (m, 1H), 7.66 (ddd, J = 8.0, 1.9, 1.0 Hz, 1H), 7.48 
– 7.27 (m, 2H), 7.05 (s, 1H), 6.53 (s, 1H), 6.05 (s, 2H). 
13C NMR (50 MHz, CDCl3): δ [ppm] = 190.73, 181.17, 150.42, 148.56, 
136.79, 135.51, 135.44, 130.39, 130.26, 125.77, 123.12, 120.30, 
109.67, 102.47, 98.09, 82.78. 
HRMS m/z: [M – H]– calcd for C16H9BrIO4–: 470.87344; found: 
470.87396. Correct isotopic pattern. 
5.1.33 1-(3-Bromophenyl)-3-hydroxy-3-(6-(trimethylstannyl)benzo[d][1,3]dioxol-5-
yl)prop-2-en-1-one (9b) 
The title compound was synthesized according to general procedure E using 6c (450 mg, 
1.4 mmol), LiHMDS (3 eq.) and 3-bromobenzoyl chloride (1 eq). The resulted residue 
was purified with flash chromatography. 
Yield   690 mg, 98% 
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Appearance  yellow solid 
Molecular formula C19H19BrO4Sn 
Molar mass  509.97100 
TLC   Rf = 0.50 (Et2O/petroleum ether, 1:4) 
1H-NMR (200 MHz, CDCl3): δ [ppm] = 16.42 (s, 1H), 8.09 (s, 1H), 7.88 (d, 
J = 7.9 Hz, 1H), 7.68 (d, J = 7.9 Hz, 1H), 7.48 (d, J = 6.5 Hz, 1H), 
7.38 (t, J = 7.9 Hz, 1H), 7.26 (d, J = 11.7 Hz, 1H), 6.74 (s, 1H), 
6.09 (s, 2H), 0.29 (s, 9H). 
13C-NMR (50 MHz, CDCl3): δ [ppm] = 191.22, 177.31, 151.56, 148.37, 
142.46, 136.52, 135.13, 135.01, 130.35, 129.87, 125.39, 123.07, 
116.32, 108.77, 101.88, 93.35, -6.39. 
HRMS m/z: [M – CH3]+ calcd for C18H16BrO4Sn+: 496.92280; found: 
496.92306. Correct isotopic pattern. 
5.1.34 3-(Benzo[d][1,3]dioxol-5-yl)-1-(3-bromophenyl)-3-hydroxyprop-2-en-1-one 
(9c) 
The title compound was synthesized according to general procedure E using 1-
(benzo[d][1,3]dioxol-5-yl)ethan-1-one (1.5 g, 9.1 mmol), LiHMDS (3 eq.) and 3-
bromobenzoyl chloride (1 eq.). 
Yield   2.82 g, 89% 
Appearance  yellow solid 
Molecular formula C16H11BrO4 
Molar mass  347.16400 
TLC   Rf = 0.46 (Et2O/petroleum ether, 1:4) 
1H-NMR (200 MHz, CDCl3): δ [ppm] = 7.88 (q, J = 1.7 Hz, 1H), 7.75 – 7.60 
(m, 1H), 7.53 – 7.34 (m, 2H), 7.31 – 7.23 (m, 1H), 7.23 – 7.08 (m, 
1H), 6.75 – 6.61 (m, 1H), 6.54 (s, 1H), 5.87 (s, 2H). 
13C-NMR (50 MHz, CDCl3): δ [ppm] = 151.34, 147.91, 136.89, 136.87, 
134.57, 129.91, 129.50, 125.19, 122.91, 122.42, 107.89, 106.85, 
101.61, 92.48. 
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HRMS m/z: [M - H]- calcd for C16H10BrO4
-: 344.97679; found: 344.97664. 
Correct isotopic pattern. 
5.1.35 3-(Benzo[d][1,3]dioxol-5-yl)-1-(3-fluorophenyl)-3-hydroxyprop-2-en-1-one (9e) 
The title compound was synthesized according to general procedure E using 1-
(benzo[d][1,3]dioxol-5-yl)ethan-1-one (500 mg, 3 mmol), LiHMDS (3 eq.) and 3-
fluorobenzoyl chloride (1 eq). 
Yield   735 mg, 84% 
Appearance  yellow solid 
Molecular formula C16H11FO4 
Molar mass  286.25840 
TLC   Rf = 0.45 (Et2O/petroleum ether, 1:4) 
1H NMR (200 MHz, CDCl3): δ [ppm] = 16.80 (s, 1H), 7.74 (dd, J = 7.8, 
1.1 Hz, 1H), 7.63 (ddd, J = 10.0, 6.0, 2.2 Hz, 2H), 7.55 – 7.37 (m, 
2H), 7.32 – 7.16 (m, 1H), 6.90 (d, J = 8.2 Hz, 1H), 6.71 (s, 1H), 
6.07 (s, 2H). 
13C NMR (50 MHz, CDCl3): δ [ppm] = 186.52, 182.20, 165.36, 160.59, 
151.79, 148.44, 130.45, 130.29, 130.02, 123.28, 122.76, 122.70, 
119.40, 118.98, 114.28, 113.82, 108.41, 107.41, 102.08, 92.88. 
19F NMR (188 MHz, CDCl3): δ [ppm] = -111.97. 
HRMS m/z: [M - H]- calcd for C16H10FO4
-: 285.05686; found: 285.05685. 
5.1.36 (6-Iodobenzo[d][1,3]dioxol-5-yl)methanol81 
In a darkened fume hood, a solution of molecular iodine (4.10 g, 16 mmol, 1.2 eq.) in 
MeOH (75 mL) was added, dropwise and via a pressure-equalized dropping funnel, to a 
magnetically stirred suspension of 1,3-benzodioxole-5-methanol (2.05 g, 13.48 mmol) 
and silver trifluoroacetate (3.60 g, 16 mmol, 1.2 eq.) in CHCl3 (75 mL) maintained at 0 ºC 
under argon. The resulting suspension was stirred vigorously at ambient temperature for 
18 h. The solids formed were removed by filtration through a pad of Celite. The pad was 
washed with CHCl3 (50 mL). The combined filtrates were washed three times with 
saturated aqueous solution of sodium thiosulfate (100 mL) then brine (100 mL) before 
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being dried over MgSO4, filtered and concentrated under reduced pressure. The residue 
was purified with flash chromatography to provide the title compound. 
Yield   2.33 g, 62% 
Appearance  white solid  
Molecular formula C8H7IO3 
Molar mass  278.04547 
TLC   Rf = 0.37 (EtOAc/petroleum ether, 1:4) 
1H-NMR (200 MHz, CDCl3): δ [ppm] = 7.23 (s, 1H), 6.99 (s, 1H), 5.98 (s, 
2H), 4.59 (s, 2H), 1.81 (s, 1H). 
5.1.37 Tetrakis(pyridine)copper(II) bis(trifluoromethanesulfonate)96 
Copper(II) trifluoromethanesulfonate (5 g, 14 mmol) was dissolved in methanol (25 mL). 
Pyridine (12 mL, 149 mmol) was added dropwise and stirred for 30 min. The exothermic 
reaction was allowed to sit in room temperature for one hour and then in fridge (5 °C) 
overnight. The blue crystalline precipitate was filtrated off. The product was 
recrystallized from a hot (40 °C) solution of pyridine in methanol (1:4 v/v) and dried 
under stream of air. 
Yield   8.5 g, 91% 
Appearance  blue solid 
Molecular formula C22H20CuF6N4O6S2 
Molar mass  678.08042 
Anal. Calcd for C22H20CuF6N4O6S2: C, 38.97; H, 2.97; N, 8.26. Found: 
C, 39.1± < 0.1; H, 3.16±0.09; N, 8.33±0.01. 
5.1.38 3-(Trimethylstannyl)benzaldehyde 
The title compound was synthesized according to general procedure B using 3-
bromobenzaldehyde (850 mg, 4.6 mmol), Pd(PPh3)4 (531 mg, 0.5 mmol, 0.1 eq.) and 
hexamethylditin (1.9 mL, 9.2 mmol, 2 eq.). The product was purified with flash 
chromatography (Et2O:petroleum ether, 1:9). 
Yield   900 mg, 73% 
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Appearance  colorless oil 
Molecular formula C10H14O3Sn 
Molar mass  268.93100 
1H-NMR (200 MHz, CDCl3): δ [ppm] = 10.03 (s, 1H), 8.19 – 7.89 (m, 1H), 
7.89 – 7.64 (m, 2H), 7.52 (t, J = 7.4 Hz, 1H), 0.34 (s, 9H). 
13C-NMR (50 MHz, CDCl3): δ [ppm] = 193.18, 143.88, 142.05, 137.09, 
135.75, 129.87, 128.61, -9.33. 
5.1.39 Trimethyl(phenyl)germane 
General procedure F: In flame dried flask n-BuLi (1 mL 2.5M in , 1.3 eq.) was added 
to a stirred solution of iodobenzene (219 µL, 2 mmol) in anhydrous Et2O (2 mL) under 
argon at -80 °C. After 30 min chlorotrimethylgermane (291 µL, 1.2 eq.) dissolved in 
anhydrous Et2O (1 mL) was added at -50 °C. The reaction was stirred for further 30 min 
and then quenched with NH4Clsat. (50 mL). The mixture was extracted with Et2O 
(3×10 mL). The organic phase was then washed with brine (50 mL) and dried over 
Na2SO4. The volatiles were then removed under reduced pressure. The resulted residue 
was used without further purification. 
Yield   248 mg, 50% 
Appearance  yellow oil 
Molecular formula C9H14Ge 
Molar mass  194.84100 
1H NMR97 (200 MHz, CDCl3): δ [ppm] = 7.55 – 7.28 (m, 5H), 0.39 (s, 9H). 
5.1.40 Methyl 4-fluorobenzoate 
4-fluorobenzoyl chloride (500 µL, 4.2 mmol) was stirred in MeOH (20 mL) at 40 °C for 
2 h. After that, the volatiles were removed under reduced pressure. The residue was used 
without further purification. 
Yield   440 mg, 67% 
Appearance  colorless oil 
Molecular formula C8H7FO2 
Molar mass  154.14040 
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1H NMR  (200 MHz, CDCl3): δ [ppm] = 8.17 – 7.95 (m, 2H), 7.21 – 6.97 (m, 
2H), 3.92 (s, 3H). 
13C NMR (50 MHz, CDCl3): δ [ppm] = 168.41, 166.27, 163.36, 132.34, 
132.16, 126.58, 126.52, 115.85, 115.42, 52.31. 
19F NMR (188 MHz, CDCl3): δ [ppm] = -105.79. 
5.1.41 Methyl 4-(trimethylstannyl)benzoate 
The title compound was synthesized according to general procedure B using methyl 4-
iodobenzoate (2 g, 7.6 mmol), Pd(PPh3)4 (0.05 eq.) and hexamethylditin (1.2 eq.). The 
product was purified with flash chromatography (Et2O:petroleum ether, 1:9). 
Yield   1.9 g, 83% 
Appearance  yellow oil 
Molecular formula C11H16O2Sn 
Molar mass  298.85700 
1H NMR (200 MHz, CDCl3): δ [ppm] = 8.19 – 7.86 (m, 2H), 7.79 – 7.37 (m, 
2H), 3.92 (s, 3H), 0.33 (s, 9H). 
13C NMR (50 MHz, CDCl3): δ [ppm] = 167.48, 149.69, 135.82, 135.82, 
129.86, 128.55, 128.55, 52.08, -9.50. 
5.1.42 tert-Butyl (S)-2-(bis(tert-butoxycarbonyl)amino)-3-(4-((tert-
butoxycarbonyl)oxy)-5-methoxy-2-(trimethylstannyl)phenyl)propanoate 
General procedure F: To a solution of tert-butyl (S)-2-((tert-butoxycarbonyl)amino)-3-
(4-((tert-butoxycarbonyl)oxy)-5-methoxy-2-(trimethylstannyl)phenyl)propanoate 
(220 mg, 0.3 mmol) in dry acetonitrile (3 mL) under argon was added 4-
dimethylaminopyridine (DMAP) (17 mg, 0.1 mmol, 0.4 eq.) and di-tert-butyl 
dicarbonate (229 mg, 1 mmol, 3 eq.). The reaction was stirred at room temperature for 
48 h, and then concentrated under vacuum. Purification by flash chromatography 
(Et2O:petroleum ether, 1:9) afforded the title compound. 
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Yield   255 mg, 86% 
Appearance  yellow oil 
Molecular formula C32H53NO10Sn 
Molar mass  730.48300 
1H NMR (200 MHz, CDCl3): δ [ppm] = 7.09 (s, 1H), 6.84 – 6.68 (m, 1H), 
5.29 (s, 3H), 4.88 (dd, J = 9.3, 6.2 Hz, 1H), 3.60 – 3.36 (m, 2H), 
1.53 (s, 9H), 1.48 (s, 9H), 1.38 (s, 18H), 0.30 (s, 9H). 
13C NMR (50 MHz, CDCl3): δ [ppm] = 169.01, 152.27, 143.78, 129.41, 
114.13, 83.26, 82.84, 81.86, 60.52, 55.74, 28.13, 28.01, 27.77, -
8.22. 
HRMS m/z: [M + Na]+ calcd for C32H53NNaO10Sn
+: 754.25836; found: 
754.25918. Correct isotopic pattern. 
5.1.43 Ethyl (S)-3-(4,5-bis((tert-butoxycarbonyl)oxy)-2-(trimethylstannyl)phenyl)-2-
(bis(tert-butoxycarbonyl)amino)propanoate 
The title compound was synthesized according to general procedure F using ethyl (S)-3-
(4,5-bis((tert-butoxycarbonyl)oxy)-2-(trimethylstannyl)phenyl)-2-((tert-
butoxycarbonyl)amino)propanoate (200 mg, 0.3 mmol), DMAP (0.4 eq.) and di-tert-
butyl dicarbonate (3 eq.). 
Yield   229 mg, 96% 
Appearance  yellow oil 
Molecular formula C34H55NO12Sn 
Molar mass  788.51900 
1H NMR (200 MHz, CDCl3): δ [ppm] = 7.23 (s, 1H), 7.15 – 6.97 (m, 1H), 
5.03 (dd, J = 9.8, 4.8 Hz, 1H), 4.21 (ddt, J = 10.3, 7.0, 3.5 Hz, 2H), 
3.52 – 3.18 (m, 2H), 1.52 (d, J = 2.5 Hz, 18H), 1.38 (s, 18H), 1.27 
(t, J = 5.8 Hz, 3H), 0.33 (s, 9H). 
13C NMR (50 MHz, CDCl3): δ [ppm] = 170.17, 152.04, 150.87, 150.72, 
143.22, 142.58, 141.37, 140.61, 130.08, 123.94, 83.54, 83.45, 
83.19, 61.57, 59.48, 37.93, 29.80, 27.96, 27.72, 14.26, -8.03. 
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HRMS m/z: [M + Na – CH2]+ calcd for C34H55NNaO12Sn+: 812.26384; 
found: 812.26458. Correct isotopic pattern. 
5.1.44 Ethyl (S)-2-(bis(tert-butoxycarbonyl)amino)-3-(5-((tert-butoxycarbonyl)oxy)-2-
(trimethylstannyl)phenyl)propanoate 
The title compound was synthesized according to general procedure F using ethyl (S)-2-
((tert-butoxycarbonyl)amino)-3-(5-((tert-butoxycarbonyl)oxy)-2-
(trimethylstannyl)phenyl)propanoate (300 mg, 0.5 mmol), DMAP (0.4 eq.) and di-tert-
butyl dicarbonate (3 eq.). 
Yield   250 mg, 71% 
Appearance  yellow oil 
Molecular formula C29H47NO9Sn 
Molar mass  672.40300 
1H NMR (200 MHz, CDCl3): δ [ppm] = 7.37 (t, J = 8.4 Hz, 1H), 7.12 – 6.97 
(m, 1H), 6.92 (d, J = 2.2 Hz, 1H), 5.02 (dd, J = 10.4, 4.5 Hz, 1H), 
4.22 (qd, J = 7.1, 2.7 Hz, 2H), 3.59 – 3.20 (m, 2H), 1.53 (s, 9H), 
1.38 (s, 18H), 1.28 (s, 3H), 0.32 (s, 9H). 
13C NMR (50 MHz, CDCl3): δ [ppm] = 170.21, 151.98, 151.90, 151.72, 
146.34, 140.06, 137.19, 122.32, 118.86, 83.34, 83.09, 61.58, 59.69, 
38.42, 29.82, 27.96, 14.28, -8.10. 
HRMS m/z: [M + Na]+ calcd for C29H47NNaO9Sn
+: 696.21650; found: 
696.21766. Correct isotopic pattern. 
5.1.45 Ethyl (S)-2-(bis(tert-butoxycarbonyl)amino)-3-(4-((tert-butoxycarbonyl)oxy)-2-
(trimethylstannyl)phenyl)propanoate 
The title compound was synthesized according to general procedure F using ethyl (S)-2-
((tert-butoxycarbonyl)amino)-3-(4-((tert-butoxycarbonyl)oxy)-2-
(trimethylstannyl)phenyl)propanoate (100 mg, 0.2 mmol), DMAP (0.4 eq.) and di-tert-
butyl dicarbonate (3 eq.) 
Yield   117 mg, 85% 
Appearance  yellow oil 
Molecular formula C29H47NO9Sn 
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Molar mass  672.40300 
1H NMR (200 MHz, CDCl3): δ [ppm] = 7.17 (d, J = 2.3 Hz, 1H), 7.12 – 6.84 
(m, 1H), 4.98 (dd, J = 9.7, 5.1 Hz, 1H), 4.21 (qd, J = 7.2, 1.9 Hz, 
1H), 3.35 (dd, J = 7.2, 4.2 Hz, 1H), 1.54 (s, 1H), 1.36 (s, 2H), 1.27 
(s, 1H), 0.33 (s, 1H). 
13C NMR (50 MHz, CDCl3): δ [ppm] = 170.19, 151.95, 151.81, 149.48, 
144.66, 142.01, 130.20, 128.49, 121.39, 83.39, 83.11, 61.54, 59.89, 
37.87, 29.79, 27.97, 27.80, 14.26, -8.10. 
HRMS m/z: [M + Na]+ calcd for C29H47NNaO9Sn
+: 696.21650; found: 
696.21700. Correct isotopic pattern. 
5.1.46 (2-Methoxyphenyl)trimethylstannane 
The title compound was synthesized according to general procedure D using 2-iodoanisol 
(131 µL, 1 mmol), n-BuLi (1.3 eq.) and trimethyltin chloride (2 eq.). The reaction was 
quenched with TBAF (1 mL, 1M solution in THF). 
Yield   150 mg, 55% 
Appearance  yellow oil 
Molecular formula C10H16OSn 
Molar mass  270.94700 
1H NMR (200 MHz, CDCl3): δ [ppm] = 7.35 (ddd, J = 9.7, 7.5, 1.7 Hz, 2H), 
7.24 – 6.94 (m, 1H), 6.94 – 6.72 (m, 1H), 3.80 (s, 3H), 0.27 (s, 9H). 
5.1.47 (3-Methoxyphenyl)trimethylstannane 
The title compound was synthesized according to general procedure D using 3-iodoanisol 
(120 µL, 1 mmol), n-BuLi (1.3 eq.) and trimethyltin chloride (2 eq.). The reaction was 
quenched with TBAF (1 mL, 1M solution in THF). 
Yield   180 mg, 66% 
Appearance  yellow oil 
Molecular formula C10H16OSn 
Molar mass  270.94700 
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1H NMR (200 MHz, CDCl3): δ [ppm] = 7.45 – 7.18 (m, 1H), 7.18 – 6.97 (m, 
2H), 6.89 (ddd, J = 8.3, 2.7, 1.1 Hz, 1H), 3.85 (s, 3H), 0.33 (s, 9H). 
5.1.48 (4-Methoxyphenyl)trimethylstannane 
The title compound was synthesized according to general procedure D using 3-iodoanisol 
(235 mg, 1 mmol), n-BuLi (1.3 eq.) and trimethyltin chloride (2 eq.). The reaction was 
quenched with TBAF (1 mL, 1M solution in THF). 
Yield   190 mg, 70% 
Appearance  yellow oil 
Molecular formula C10H16OSn 
Molar mass  270.94700 
1H NMR (200 MHz, CDCl3): δ [ppm] = 7.64 – 7.20 (m, 2H), 6.94 (ddd, J = 
6.5, 4.1, 1.9 Hz, 2H), 3.82 (s, 3H), 0.28 (s, 9H). 
5.1.49 1-(2,4-Dinitrophenyl)-pyridinium chloride 
Pyridine (457 µL, 5.7 mmol, 1.1 eq.) was dissolved in acetone (2.5 mL) and stirred, while 
2,4-dinitrochlorobenzene (1 g, 5 mmol, 1 eq.) was added to the reaction mixture. The 
mixture was heated under reflux 24 h and cooled to room temperature. The precipitate 
produced was filtered under suction and washed with n-hexane to obtain the title 
compound. 
Yield   1.27 g, 91% 
Appearance  yellow solid 
Molecular formula C11H8ClN3O4 
Molar mass  281.65200 
1H NMR (300 MHz, DMSO-d6): δ [ppm] = 9.48 (dd, J = 6.8, 1.2 Hz, 2H), 
9.12 (d, J = 2.5 Hz, 1H), 9.03–8.90 (m, 2H), 8.58–8.38 (m, 3H). 
13C NMR (75 MHz, DMSO-d6): δ [ppm] = 149.03, 148.73, 146.02, 143.01, 
138.64, 131.88, 130.08, 127.94, 121.31.  
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5.2 Radiochemistry 
5.2.1 General procedures 
5.2.1.1 Materials and Methods 
All labeling experiments were repeated at least 3 times. Standard deviations (SD) were 
calculated by the least-square method. All experiments were carried out as one-pot 
procedure and not by using aliquots. The reaction mixture was always quenched with 
water (2-4 mL) to dissolve any [18F]fluoride on the reaction vessel walls. The loss of radio 
activity on the reaction vessel walls did not exceed 13±2% from the starting activity 
(decay corrected) in all experiments. All radiochemical yields (RCY) are decay corrected 
and radiochemical purities (RCP) were determined after purification. RCY for model 
compounds and in optimization experiments was determined by HPLC without 
purification. 
5.2.1.2 High-performance liquid chromatography (HPLC) 
For manual synthesis, the following system was used: 
Ultimate® 3000 HPLC system from Thermo Scientific (Sunnyvale, USA) with Ultimate® 
3000 LPG-3400A pump, Ultimate® 3000 VWD-3100 UV/Vis detector and -detector 
Gabi Star from Raytest GmbH (Straubenhardt, Deutschland) were used. The volume of 
injection was 20 μL. UV-detection was at  = 210 nm wave length. 
The following column were used: 
• Chromolith® SpeedROD RP-18 endcapped 50×4.6 mm from Merck KGaA 
(Darmstadt, Germany). 
• ProntoSIL C18 ace-EPS 125×4.6 mm from Bischoff Analysentechnik und -geräte 
GmbH, Leonberg, Germany. 
• Gemini® 5 µm C18 110 Å, LC Column 250×4.6 mm from Phenomenex Inc. 
• Gemini® 5 µm C18 110 Å, LC Column 250×10 mm from Phenomenex Inc. 
In the automated synthesis, the following system was used: 
WellChrom Spectro-photometer K-2501 UV/Vis detector, BlueShadow Pump 80P from 
KNAUER Wissenschaftliche Geräte GmbH, Berlin, Germany and AD 1422 PIN-
photodiode and scintillator detector from Eckert & Ziegler Strahlen- und Medizintechnik 
AG, Berlin, Germany was connected directly to the automated module. 
For automated synthesis, the following C18 with polar endcapping column were used: 
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• Synergi™ 4 µm Hydro-RP 80 Å, LC Column 250×10 mm from Phenomenex Inc. 
• Synergi™ 4 µm Hydro-RP 80 Å, LC Column 150×21.2 mm, AXIA™ Packed 
from Phenomenex Inc. 
5.2.1.3 Solid Phase Extraction Cartridges (SPE) and anion exchange cartridges (AX) 
Strata™-X-A 33 µm Polymeric Strong Anion, 30 mg/1 mL, tubes from Phenomenex Inc; 
Chromafix® (PS-HCO3) cartridge from Macherey-Nagel GmbH & Co.KG and Sep-Pak
® 
Accell plus QMA Carbonate Plus Light Cartridge from Waters Co. These anion exchange 
cartridges were preconditioned with 1 mL water before it was dried with a stream of air. 
Strata™-X 33 µm Polymeric Reversed Phase, 30 mg/1 mL, tubes from Phenomenex Inc. 
and Sep-Pak C18 Plus Light Cartridge, 130 mg Sorbent per Cartridge, 55-105 µm Particle 
Size from Waters Co. were preconditioned with 1 mL ethanol followed by 10 mL water. 
Sep-Pak C18 Plus Long Cartridge, 820 mg Sorbent per Cartridge, 55-105 µm Particle 
Size from Waters Co. was preconditioned with 2 mL ethanol followed by 20 mL water. 
5.2.1.4 Solvents and Reagents 
HPLC solvents were purchased from Merck KGaA (Darmstadt, Germany). Pure water to 
precondition the cartridges and purify the labeled products was obtained from Berlin-
Chemie AG. MENARINI Group. Other solvents were obtained from Sigma-Aldrich 
GmbH (Steinheim, Germany) as anhydrous solvents and used without further 
purification. 
5.2.1.5 Miscellaneous Information 
Radioactivity was measured with a CRC®-55tR Dose Calibrator from Capintec, Inc or 
the Curiementor 2 from PTW GmbH (Freiburg, Germany). 
5.2.1.6 Production of fluorine-18 
No-carrier-added [18F]F- (2-3 GBq) was produced via the nuclear reaction 18O(p,n)18F by 
bombardment of 0.5-1 mL 18O-enriched water for 2-30 min with a 17 MeV proton beam 
and 15-35 μA current at the MC 16 cyclotron (Scanditronix, Uppsala, Sweden) of the 
Max Planck Institute for Metabolic Research, or Baby Cyclotron BC 1710 (Japan Steel 
Works Ltd. [JSW], Japan) of the institute of nuclear chemistry (INM-5) in 
Forschungszentrum Jülich.  
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5.2.2 Screening of pyrazole [18F]1d synthesis 
 
5.2.2.1 Reaction temperature 
Reaction conditions: [18F]3a (10-50 MBq), 2b (40 µmol), LiOtBu (12 µmol), 20 min, 
MeCN, volume (500 µL). 
Reaction temperature [°C] RCY [%] 
65 7±2 
80 50±4 
95 60±10 
110 60±17 
5.2.2.2 Solvent 
Reaction conditions: [18F]3a (10-50 MBq), 2b (40 µmol), LiOtBu (12 µmol), 25 min, 
95 °C, volume (500 µL). 
Solvent RCY [%] 
MeCN 67±3 
DMSO 19±1 
Dioxane 47±5 
PC 53±6 
5.2.2.3 Reaction time 
Reaction conditions: [18F]3a (10-50 MBq), 2b (40 µmol), LiOtBu (12 µmol), 95 °C, 
MeCN, volume (500 µL). 
Reaction time [min] RCY [%] 
15 35±4 
20 60±10 
25 67±3 
30 66±2 
5.2.2.4 Base 
Reaction conditions: [18F]3a (10-50 MBq), 2b (40 µmol), base (12 µmol), 20 min, 80 °C, 
MeCN, volume (500 µL). 
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Base RCY [%] 
NaOH 44±5 
K2CO3 42±4 
LiOtBu 50±4 
DBU 33±2 
 
5.2.3 Synthesis of 5-(3-bromophenyl)-3-(6-[18F]fluorobenzo[d][1,3]dioxol-5-yl)-1H-
pyrazole ([18F]1b) 
5.2.3.1 6-[18F]Fluorobenzo[d][1,3]dioxole-5-carbaldehyde 
[18F]F– (1000 MBq) was fixed on QMA anion exchange cartridge. The cartridge was 
rinsed with MeOH (2 mL) and dried with air stream. [18F]F– was then eluted using 
Et4NBC (5 mg, 26 µmol) in MeOH (1 mL). MeOH was removed under reduced pressure 
at 100 °C within 5 min. Then a solution of 6-nitropiperonal (5 mg, 25.6 µmol) in DMSO 
(400 µL) was added to the dry salt. The V-vial was allowed to stir at 130 °C for 10 min. 
after that the reaction mixture was cooled to room temperature and purified with StrataX 
RP cartridge. The recovered acetonitrile solution was diluted with water and purified over 
HPLC (semi prep Gemini 8 mL/min, 18% MeCN). The purified fraction was diluted with 
water, concentrated on StrataX RP cartridge and eluted with MeOH (300 µL). 6-
[18F]fluoropiperonal (131.7 MBq, RCY 22%, RCP 99%). 
5.2.3.2 N'-((6-[18F]Fluorobenzo[d][1,3]dioxol-5-yl)methylene)-4-
methylbenzenesulfonohydrazide 
To the methanolic solution of 6-[18F]fluoropiperonal (131.7 MBq), tosylhydrazide 
(10 mg, 53.7 µmol) was added and the mixture was stirred at 80 °C for 10 min. after that 
the reaction mixture was quenched with water (6 mL) and filtered through PTFE filter 
and purified using StrataX RP cartridge. The cartridge was rinsed with 10 mL water and 
finally 6-[18F]fluorotosylhydrazone was eluted with MeCN (300 µL). 6-
[18F]fluorotosylhydrazone (60.12 MBq, RCY 53%, RCP 99%). 
5.2.3.3 Synthesis of 5-(3-bromophenyl)-3-(6-[18F]fluorobenzo[d][1,3]dioxol-5-yl)-1H-
pyrazole ([18F]1b) 
LiOtBu (5 mg, 62 µmol) and 2a (10 µL, 80 µmol) were added to MeCN solution of 6-
[18F]fluorotosylhydrazone (60.12 MBq) and stirred at 95 °C for 25 min. then the reaction 
mixture was cooled to room temperature, diluted with MeCN (50% v/v) and purified over 
HPLC. The purified fraction was concentrated on StrataX RP cartridge and eluted with 
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EtOH (300 µL). Then it was purified over HPLC (50% MeCN+0.1% TFA). The purified 
fraction was concentrated on StrataX RP cartridge and eluted with EtOH (300 µL). The 
overall RCY was 1%. 
5.2.4 Screening 18F-fluorodestannylation 
 
5.2.4.1 Recovery of [18F]fluoride from anion exchange cartridge 
Recovery conditions: 50 MBq [18F]Fluoride fixed on QMA-CO3 from the male side, then 
rinsed with MeOH (1 mL) in the same direction, after that [18F]-fluoride was recovered 
with methanolic solution of Et4NX (500 µL). 
[µmol] 
18F-Recovery [%] 
Et4NBC Et4NTf Et4NBF4 Et4NI 
60 98 98   
30 94 94 93 99 
15 96 95 97 97 
5 94 96 97 92 
2,5 95 96 97 96 
0,5 81 76 80 89 
5.2.4.2 Alcohol screening 
Reaction conditions: [18F]Fluoride (~50 MBq) was recovered from QMA-CO3 with 
alcoholic solution (300 µL) of Et4NOTf (11 µmol), 10b (60 µmol), Cu(OTf)2(py)4 
(30 µmol), 100 °C, 10 min, ROH:DMA/3:7 (volume 1 mL). 
ROH RCY [%] 18F Recovered [%] Rest on cartridge [%] 
MeOH 11±4 85±1 1±0 
EtOH 45±8 83±1 5±1 
TFE 0 84±2 4±2 
n-PrOH 62±6 77±4 11±2 
i-PrOH 70±3 72±5 16±3 
n-BuOH 72±8 73±8 19±1 
s-BuOH 66±7 47±6 37±7 
t-BuOH 80±4 10±1 78±1 
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n-PenOH 75±10 68±4 18±5 
n-HexOH 55±2 64±4 21±4 
 
5.2.4.3 Anion exchange cartridge 
Reaction conditions: [18F]Fluoride (~50 MBq) was recovered from anion exchange 
cartridge with n-BuOH solution (300 µL) of Et4NOTf (11 µmol), 10b (60 µmol), 
Cu(OTf)2(py)4 (30 µmol), 100 °C, 10 min, n-BuOH:DMA/3:7 (volume 1 mL). 
 
QMA-
CO3 
Strata X-
CO3 
Strata X-
HCO3 
Chromafix PS-
HCO3 
Rest on the cartridge 
[%] 
19±1 14±1 18±2 35±2 
18F recovery [%] 73±8 81±1 68±9 57±3 
RCY [%] 69±4 24±15 37±10 42±5 
 
5.2.4.4 18F-Fluorination reagents 
Reaction conditions: [18F]Fluoride (~50 MBq) was recovered from QMA-CO3 with n-
BuOH solution (300 µL) of 18F-Fluorination reagents (11 µmol), 10b (60 µmol), 
Cu(OTf)2(py)4 (30 µmol), 100 °C, 10 min, n-BuOH:DMA/3:7 (volume 1 mL). In the case 
of KOTf, K222 (33 µmol) was added. 
 Et4NOTf Et4NBC KOTf/K222 Bu4POMs 
Rest on the cartridge [%] 19±1 18±2 9±2 14±4 
18F recovery [%] 72±8 71±1 81±5 76±2 
RCY [%] 69±4 63±9 9±1 60±11 
 
5.2.4.5 Reaction time 
Reaction conditions: [18F]Fluoride (~50 MBq) was recovered from QMA-CO3 with n-
BuOH solution (300 µL) of Et4NOTf (11 µmol), 10b (60 µmol), Cu(OTf)2(py)4 
(30 µmol), 100 °C, n-BuOH:DMA/3:7 (volume 1 mL). 
Reaction time [min] RCY [%] 
5 76±4 
10 72±8 
15 72±9 
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20 75±2 
25 60±1 
 
5.2.4.6 Reaction temperature optimization 
Reaction conditions: [18F]Fluoride (~50 MBq) was recovered from QMA-CO3 with n-
BuOH solution (300 µL) of Et4NOTf (11 µmol), 10b (60 µmol), Cu(OTf)2(py)4 
(30 µmol), 10 min, n-BuOH:DMA/3:7 (volume 1 mL). 
Reaction temperature [°C] RCY [%] 
80 34±2 
90 45±11 
100 72±8 
110 65±5 
120 60±5 
 
5.2.4.7 Aprotic solvent optimization 
Reaction conditions: [18F]Fluoride (~50 MBq) was recovered from QMA-CO3 with n-
BuOH solution (300 µL) of Et4NOTf (11 µmol), 10b (60 µmol), Cu(OTf)2(py)4 
(30 µmol), 100 °C, 10 min, n-BuOH:solvent/3:7 (volume 1 mL). 
Solvent RCY [%] 
DMA 72±8 
NMP 73±3 
TMU 28±2 
DMF 9±3 
DMSO 7±2 
Pyridine 0 
NMF 0 
t-BuOH 0 
 
5.2.4.8 Water content 
Reaction conditions: [18F]Fluoride (~50 MBq) was recovered from QMA-CO3 with n-
BuOH solution (300 µL) of Et4NOTf (11 µmol), 10b (60 µmol), Cu(OTf)2(py)4 
(30 µmol), 100 °C, 10 min, n-BuOH:DMA/3:7 + X µL water (volume 1 mL). 
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Water content [µL/1 mL] RCY [%] 
0 73±8 
5 35±2 
10 16±1 
15 9±1 
 
5.2.4.9 n-BuOH content 
Reaction conditions: [18F]Fluoride (~50 MBq) was recovered from QMA-CO3 with n-
BuOH solution (300 µL) of Et4NOTf (11 µmol), 10b (60 µmol), Cu(OTf)2(py)4 
(30 µmol), 100 °C, 10 min, n-BuOH:DMA/X:Y (volume 1 mL). 
n-BuOH part from 10 RCY [%] 
0 84±4 
1 85±2 
2 78±4 
3 72±8 
4 58±9 
5 42±2 
 
Reaction conditions: [18F]Fluoride (~50 MBq) was recovered from QMA-CO3 with 
MeOH solution (500 µL) of Et4NOTf (11 µmol), then MeOH was evaporated. 10b 
(30 µmol), Cu(OTf)2(py)4 (30 µmol), 100 °C, 10 min, solvent (volume 1 mL). 
Solvents RCY [%] 
n-BuOH:DMA (1:9) 73±2 
t-BuOH:DMA (1:9) 73±2 
DMA 72±4 
 
5.2.4.10 Precursor concentration 
Reaction conditions: [18F]Fluoride (~50 MBq) was recovered from QMA-CO3 with n-
BuOH solution (300 µL) of Et4NOTf (11 µmol), 10b (X µmol), Cu(OTf)2(py)4 
(30 µmol), 100 °C, 10 min, n-BuOH:DMA/3:7 (volume 1 mL). 
Precursor concentration 
[µmol/mL] 
RCY [%] 
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60 73±8 
40 78±1 
30 70±4 
20 63±2 
10 44±2 
 
5.2.4.11 Cu(OTf)2(py)4 concentration 
Reaction conditions: [18F]Fluoride (~50 MBq) was recovered from QMA-CO3 with n-
BuOH solution (300 µL) of Et4NOTf (11 µmol), 10b (30 µmol), Cu(OTf)2(py)4 
(X µmol), 100 °C, 10 min, n-BuOH:DMA/3:7 (volume 1 mL). 
Cu(OTf)2(py)4 
concentration [µmol/mL] 
RCY [%] 
40 61±9 
30 70±4 
20 66±5 
10 54±2 
 
5.2.5 General procedure for model compounds and [18F]1c 
[18F]Fluoride (50-100 MBq) was loaded on an anion exchange cartridge from the male 
side (QMA carbonate, precedenced with 1 mL water and dry with air). The cartridge was 
rinsed with MeOH (1 mL) and dried with air, then [18F]fluoride was eluted with 
methanolic solution (500 µL) of Et4NOTf (2.79 mg, 10 µmol) into V-vial. Methanol was 
removed under reduced pressure (600 mBar) with a stream of argon at 100 °C within 
3 min. After removing methanol the pressure was reduced to 50 mBar and the V-vial was 
purged with air. To the dry salt Cu(OTf)2(py)4 (20.34 mg, 30 µmol) and the 
corresponding precursor (30 µmol) dissolved in DMA (1 mL) was added. The reaction 
mixture was stirred at 100 °C for 10 min, and then it was cooled to room temperature in 
an ice bath. The reaction mixture was quenched with water (4 mL) and a sample was 
taken to determine the RCY. 
Compound RCY [%] HPLC conditions 
 
72±4(SnMe3) 
88±1(SnBu3) 
SpeedRod, tR = 4.87 min, gradient: 0–
2 min: 5% MeCN, 2–2.5 min: 5–20% 
MeCN, 2.5–6 min: 20% MeCN, 6–
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7 min: 20–70% MeCN, 7–9 min: 70% 
MeCN 
 
17±1 
SpeedRod, tR = 6.35 min, XX% aq. 
MeCN, 
flow rate: 3 mL/min 
 
16±1 
SpeedRod, tR = 4.32 min, 25% aq. 
MeCN, 
flow rate: 1.5 mL/min 
 
84±2 
SpeedRod, tR = 6.03 min, 25% aq. 
MeCN, 
flow rate: 1.5 mL/min 
 
59±3(SnMe3) 
44±2(SnBu3) 
SpeedRod, tR = 5.12 min, 25% aq. 
MeCN, 
flow rate: 1.5 mL/min 
 
34±3 
SpeedRod, tR = 4.92 min, 25% aq. 
MeCN, 
flow rate: 1.5 mL/min 
 
62±8 
Gemini 250×4.6 mm, tR = 7.3 min, 50% 
aq. MeCN+0.1% TFA, 
flow rate: 2 mL/min 
 
5.2.6 Optimization of 18F-fluorodestannylation of amino acid derivatives precursors 
 
5.2.6.1 Cu(OTf)2(py)4 concentration 
Reaction Conditions: [18F]Fluoride (50-100 MBq), Et4NOTf (11 µmol), OMFD (di-Boc) 
precursor (30 µmol), Cu(OTf)2(py)4, 100 °C, 10 min, n-BuOH:DMA 3:7 (reaction 
volume 1 mL). 
Cu(OTf)2(py)4:Precursor [eq.] RCY [%] 
1:1 22 
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1.5:1 24 
2:1 27 
3:1 25 
 
5.2.6.2 Solvent optimization 
Reaction Conditions: [18F]Fluoride (50-100 MBq), Et4NOTf (11 µmol), OMFD 
precursor (30 µmol), Cu(OTf)2(py)4 (30 µmol), 100 °C, 10 min, solvents (reaction 
volume 1 mL). 
Solvent 
RCY [%] 
OMFD (di-Boc) OMFD (tri-Boc) 
DMA 6 78 
n-BuOH:DMA (1:9) 20 74 
n-BuOH:DMA (3:7) 22 66 
 
5.2.7 General procedure for radiofluorinated amino acid derivatives synthesis 
[18F]Fluoride (200-300 MBq) was loaded on an anion exchange cartridge from the male 
side (QMA carbonate, precondenced with 1 mL water and dry with air). The cartridge 
was rinsed with MeOH (1 mL) and dried with air, then [18F]fluoride was eluted with 
methanolic solution (500 µL) of Et4NOTf (2.79 mg, 10 µmol) into V-vial. Methanol was 
removed under reduced pressure (600 mBar) with a stream of air at 100 °C within 5 min. 
To the dry salt Cu(OTf)2(py)4 (40.68 mg, 60 µmol) and the corresponding precursor 
(30 µmol) dissolved in DMA (1 mL) was added. The reaction mixture was stirred at 
100 °C for 10 min, and then it was cooled to room temperature in an ice bath. The reaction 
mixture was quenched with water (2 mL) and loaded in Sep-Pak C18 Plus Light 
Cartridge. The cartridge was washed with 5 mL water and the product was eluted with 
1 mL EtOH. HBr (48%, 1 mL) (or HCl, 38% in the case of OMFD) was added and stirred 
at 130 °C for 10 min. The mixture was cooled to room temperature and then quenched 
with water. 
Compound 
RCY 
[%] 
HPLC conditions 
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37 
ProntoSil, tR = 4.1 min, phosphate buffer with 4% 
EtOH (pH 2.5), flow rate: 1 mL/min 
 
55 
ProntoSil, tR = 5.88 min, phosphate buffer with 
4% EtOH (pH 2.5), flow rate: 1 mL/min 
 
60 
ProntoSil, tR = 5.66 min, phosphate buffer with 
4% EtOH (pH 2.5), flow rate: 1 mL/min 
 
78 
ProntoSil, tR = 7.05 min, phosphate buffer with 
4% EtOH (pH 2.5), flow rate: 1 mL/min 
 
5.2.8 Automated synthesis of radiofluorinated amino acid derivatives 
[18F]Fluoride (5-10 GBq) was load on QMA-CO3 cartridge from the female side. After 
that the cartridge was rinsed with anhydrous MeOH (2 mL) using the same path. In the 
reverse direction [18F]fluoride was recovered using methanolic solution (700 µL) of 
Et4NOTf (5 mg, 18 µmol) to the first reactor. After removing methanol under a stream of 
dry air (550 mbar) at 100 °C the corresponding precursor (30 µmol) and Cu(OTf)2(py)4 
(40.7 mg, 60 µmol) were added without precooling. After 10 min, the reaction mixture 
was cooled to 35 °C and quenched with water (1 mL). The mixture in the first reactor was 
passed through Sep-Pak C18 Plus Long cartridge. The cartridge was rinsed with water 
(12 mL), and the retained activity was then recovered with DCM (2 mL) into the second 
reactor. DCM was removed under reduced pressure of helium (600 mbar) at 100 °C 
within 3 min followed by the addition of HBr (48%, 1 mL) or HCl (38%, 1 mL, in the 
case of OMFD) then increasing the temperature to 130 °C for further 10 min. After 
finishing the hydrolysis, the mixture was diluted with NaOH (45% w/w, 300 µL) and 
HPLC mobile phase (3 mL). Finally, the diluted mixture was loaded on the HPLC for 
purification. Column: Synergi™ 4 µm Hydro-RP 80 Å, flow: 5 ml/min, mobile phase: 
sodium phosphate buffer (pH 2.45). 
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Compound 
RCY 
[%] 
HPLC conditions 
 
57 
ProntoSil, tR = 4.1 min, phosphate buffer with 4% 
EtOH (pH 2.5), flow rate: 1 mL/min 
 
41 
ProntoSil, tR = 5.88 min, phosphate buffer with 
4% EtOH (pH 2.5), flow rate: 1 mL/min 
 
44 
ProntoSil, tR = 5.66 min, phosphate buffer with 
4% EtOH (pH 2.5), flow rate: 1 mL/min 
 
32 
ProntoSil, tR = 7.05 min, phosphate buffer with 
4% EtOH (pH 2.5), flow rate: 1 mL/min 
 
5.2.9 Determination of specific activity and tin and copper content 
The molar activities (MA) were calculated by one point calibration method determined 
from the peak area in the UV-HPLC chromatograms (λ= 230 nm). 
The contents of tin and copper were determined by Agilent 7900 ICP-MS. The solution 
of amino acid derivatives obtained after HPLC purification was concentrated under 
reduced pressure, the residue was then dissolved in water (1 mL). The measured samples 
were diluted 1:100. 
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Appendix I: Chromatograms 
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Chromatogram 1 [18F]1d. 
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Chromatogram 2 [18F]4c if 6-nitropiperonal was reduced to 6-aminopiperonal. 
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Chromatogram 3 [18F]3b. 
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Chromatogram 4 [18F]1b by the three step synthesis if iron was used in the first step. 
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Chromatogram 5 [18F]1b synthesized by three step synthesis. 
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Chromatogram 6 [18F]fluorobenzene. 
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Chromatogram 7 4-[18F]fluoroanisol. 
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Chromatogram 8 3-[18F]fluoroanisol. 
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Chromatogram 9 2-[18F]fluoroanisol. 
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Chromatogram 10 3-[18F]FBA. 
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Chromatogram 11 Methyl 4-[18F]fluorobenzoate. 
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Chromatogram 12 [18F]1c with radioactivity reference peak. 
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Automated radiosynthesis of amino acids 
 
Chromatogram 13 2-[18F]F-Tyr preparative HPLC. 
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Chromatogram 14 2-[18F]F-Tyr analytical HPLC. 
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Chromatogram 15 6-[18F]FMT preparative HPLC. 
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Chromatogram 16 6-[18F]FMT analytical HPLC. 
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Chromatogram 17 6-[18F]FDOPA preparative HPLC (Synergi™ 4 µm Hydro-RP 80 Å, LC Column 250×10 mm). 
 
 
Chromatogram 18 6-[18F]FDOPA preparative HPLC (Synergi™ 4 µm Hydro-RP 80 Å, LC Column 150×21.2 mm). 
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Chromatogram 19 6-[18F]FDOPA analytical HPLC. 
 
 
Chromatogram 20 6-[18F]OMFD preparative HPLC. 
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Chromatogram 21 6-[18F]OMFD analytical HPLC. 
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Appendix II 
MS of the crude mixture of 1h. 
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NMR of crude mixture of 6-N,N,N-trimethylbenzo[d][1,3]dioxol-5-aminium salt. 
Mixture (1:3) of 6-N,N-dimethylaminopiperonal and 6-N,N,N-
trimethylbenzo[d][1,3]dioxol-5-aminium salt. 
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